<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Appl Microbiol Biotechnol</journal-id>
      <journal-title>Applied Microbiology and Biotechnology</journal-title>
      <issn pub-type="ppub">0175-7598</issn>
      <issn pub-type="epub">1432-0614</issn>
      <publisher>
        <publisher-name>Springer-Verlag</publisher-name>
        <publisher-loc>Berlin/Heidelberg</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">17704915</article-id>
      <article-id pub-id-type="pmc">2039825</article-id>
      <article-id pub-id-type="publisher-id">1142</article-id>
      <article-id pub-id-type="doi">10.1007/s00253-007-1142-2</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Mini-Review</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Properties, production, and applications of camelid single-domain antibody fragments</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes">
          <name name-style="western">
            <surname>Harmsen</surname>
            <given-names>M. M.</given-names>
          </name>
          <address>
            <phone>+31-32-238436</phone>
            <fax>+31-32-238961</fax>
            <email>michiel.harmsen@wur.nl</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>De Haard</surname>
            <given-names>H. J.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <aff id="Aff1"><label>1</label>Institute for Animal Science and Health (ID-Lelystad) of Wageningen University and Research Centre, Edelhertweg 15, 8219 PH Lelystad, The Netherlands </aff>
        <aff id="Aff2"><label>2</label>Ablynx N.V., Technologiepark 4, 9052 Zwijnaarde, Belgium </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>18</day>
        <month>8</month>
        <year>2007</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <month>11</month>
        <year>2007</year>
      </pub-date>
      <volume>77</volume>
      <issue>1</issue>
      <fpage>13</fpage>
      <lpage>22</lpage>
      <history>
        <date date-type="received">
          <day>13</day>
          <month>6</month>
          <year>2007</year>
        </date>
        <date date-type="rev-recd">
          <day>25</day>
          <month>7</month>
          <year>2007</year>
        </date>
        <date date-type="accepted">
          <day>30</day>
          <month>7</month>
          <year>2007</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; Springer-Verlag 2007</copyright-statement>
      </permissions>
      <abstract>
        <p>Camelids produce functional antibodies devoid of light chains of which the single N-terminal domain is fully capable of antigen binding. These single-domain antibody fragments (VHHs or Nanobodies&#xAE;) have several advantages for biotechnological applications. They are well expressed in microorganisms and have a high stability and solubility. Furthermore, they are well suited for construction of larger molecules and selection systems such as phage, yeast, or ribosome display. This minireview offers an overview of (1) their properties as compared to conventional antibodies, (2) their production in microorganisms, with a focus on yeasts, and (3) their therapeutic applications.</p>
      </abstract>
      <kwd-group>
        <title>Keywords</title>
        <kwd>Single-domain</kwd>
        <kwd>Microbial production</kwd>
        <kwd>Yeast</kwd>
        <kwd>Glycosylation</kwd>
      </kwd-group>
      <custom-meta-wrap>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>&#xA9; Springer-Verlag 2007</meta-value>
        </custom-meta>
      </custom-meta-wrap>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1" sec-type="introduction">
      <title>Introduction</title>
      <p>The field of recombinant antibody technology has rapidly progressed during the last two decades, mainly because of the interest in their human therapeutic use. The ability to select specific human antibodies by display technologies and to improve their affinity, stability, and expression level by molecular evolution has further boosted the field. Whole antibodies are complex molecules that consist of heavy and light chains (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>a). They contain an N-linked oligosaccharide attached to the second heavy-chain constant domain (CH2) that is essential for antibody effector functions such as antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytolysis (CDC), and for retaining a long serum half-life.
<fig id="Fig1"><label>Fig.&#xA0;1</label><caption><p>Schematic diagram of conventional (<bold>a</bold>) and heavy-chain (<bold>b</bold>) antibodies and fragments thereof. Variable domains derived from the antibody heavy (<italic>VH</italic>) and light (<italic>VL</italic>) chains are <italic>shaded dark gray</italic> and <italic>light gray</italic>, respectively, whereas constant domains (<italic>CH</italic> and <italic>CL</italic>) are not shaded. Note the absence of the light chain and CH1 domain in heavy-chain antibodies. Antibody domains that pair by noncovalent interactions are indicated by overlaying them. The B-subunits of naturally pentamerizing toxins that are used to generate pentabodies are indicated as <italic>hatched spheres</italic></p></caption><graphic position="anchor" xlink:href="253_2007_1142_Fig1_HTML" id="MO1"/></fig></p>
      <p>Although isolated antibody heavy (Utsumi and Karush <xref ref-type="bibr" rid="CR79">1964</xref>) and light chains (Yoo et al. <xref ref-type="bibr" rid="CR92">1967</xref>) can retain antigen-binding specificity, their affinity and solubility is often reduced (Ward et al. <xref ref-type="bibr" rid="CR89">1989</xref>). However, the paired N-terminal variable domains of heavy (VH) and light (VL) chains are sufficient for antigen binding (Sundberg and Mariuzza <xref ref-type="bibr" rid="CR75">2002</xref>). Such antibody fragments can be produced as monovalent antibody fragment (Fab) or as single-chain Fv (scFv) where the VH and VL domains are joined by a polypeptide linker (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>a). Their production in microbial cells is often cumbersome, especially when producing multivalent formats, because of the requirement for domain association.</p>
      <p>The discovery that camelids (bactrian camels, dromedaries, and llamas) produce functional antibodies devoid of light chains (Hamers-Casterman et al. <xref ref-type="bibr" rid="CR30">1993</xref>) formed a further breakthrough because their single N-terminal domain (VHH, also referred to as Nanobody&#xAE;) binds antigen without requiring domain pairing. These heavy-chain antibodies also lack the CH1 domain, which in a conventional antibody associates with the light chain and to a lesser degree interacts with the VH domain (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>b). Although single-domain antibodies later were also identified in particular cartilaginous fish (Greenberg et al. <xref ref-type="bibr" rid="CR28">1995</xref>), most research on the biotechnological application of single-domain antibodies was done using camelids because of their ease of handling, including immunization. Methods to isolate antigen-specific VHHs from immune (Arbabi-Ghahroudi et al. <xref ref-type="bibr" rid="CR2">1997</xref>; Van der Linden et al. <xref ref-type="bibr" rid="CR82">2000a</xref>), nonimmune (Tanha et al. <xref ref-type="bibr" rid="CR76">2002</xref>; Yau et al. <xref ref-type="bibr" rid="CR91">2003</xref>; Verheesen et al. <xref ref-type="bibr" rid="CR87">2006</xref>), or semisynthetic (Goldman et al. <xref ref-type="bibr" rid="CR27">2006</xref>) libraries using phage, yeast, or ribosome display are now well established. For further reading on these topics, we refer to recently published reviews (Muyldermans <xref ref-type="bibr" rid="CR49">2001</xref>; Dufner et al. <xref ref-type="bibr" rid="CR18">2006</xref>).</p>
    </sec>
    <sec id="Sec2">
      <title>Properties</title>
      <p>Sequence analysis (Hamers-Casterman et al. <xref ref-type="bibr" rid="CR30">1993</xref>; Muyldermans et al. <xref ref-type="bibr" rid="CR50">1994</xref>; Vu et al. <xref ref-type="bibr" rid="CR88">1997</xref>; Harmsen et al. <xref ref-type="bibr" rid="CR32">2000</xref>) and elucidation of the crystal structure (Desmyter et al. <xref ref-type="bibr" rid="CR15">1996</xref>, <xref ref-type="bibr" rid="CR16">2001</xref>; Spinelli et al. <xref ref-type="bibr" rid="CR71">1996</xref>) has revealed several structural features of VHH domains. Similar to conventional VH domains, VHHs contain four framework regions (FRs) that form the core structure of the immunoglobulin domain and three complementarity-determining regions (CDRs) that are involved in antigen binding. This contrasts with shark single-domain antibodies that have a vestigial CDR2 that does not contribute to antigen binding (Streltsov et al. <xref ref-type="bibr" rid="CR74">2004</xref>). As compared to human VH domains, the VHH FRs show a high sequence homology of more than 80%, and their 3D structures can be superimposed (Muyldermans et al. <xref ref-type="bibr" rid="CR51">2001</xref>; Holliger and Hudson <xref ref-type="bibr" rid="CR39">2005</xref>).</p>
      <p>The most characteristic feature of VHHs is the presence of amino acid substitutions at four FR2 positions (positions 37, 44, 45, and 47; Kabat numbering) that are conserved in conventional VH domains and that are involved in forming the hydrophobic interface with VL domains. Occasionally, antigen-binding single-domain antibody fragments that lack these characteristic FR2 substitutions are isolated from camelids. These fall into two groups. The low-affinity binders isolated from a nonimmune library originated from conventional antibodies, presumably because of the polymerase chain reaction crossover cloning artifact, as they were linked to the CH1 domain (Tanha et al. <xref ref-type="bibr" rid="CR76">2002</xref>). We refer to these as VHH-like conventional VHs. However, such single-domain antibody fragments with conventional-like FR2 sequences that bind antigen with high affinity are isolated from immune libraries with the high efficiency of about 10% (Conrath et al. <xref ref-type="bibr" rid="CR6">2001a</xref>; Saerens et al. <xref ref-type="bibr" rid="CR67">2004</xref>; Harmsen et al. <xref ref-type="bibr" rid="CR33">2005a</xref>, <xref ref-type="bibr" rid="CR36">2007</xref>), which equals their presence in unselected libraries (Harmsen et al. <xref ref-type="bibr" rid="CR32">2000</xref>). This is not expected when such clones originate from a cloning artifact. Unlike the clones isolated by Tanha et al. (<xref ref-type="bibr" rid="CR76">2002</xref>), these clones often contain a hydrophilic residue (mostly arginine) at position 103. This substitution is probably important for their single-domain nature (Desmyter et al. <xref ref-type="bibr" rid="CR16">2001</xref>) because conventional antibodies contain a highly conserved hydrophobic residue (tryptophan) at this position that contacts VL. This suggests that these represent functional VHH domains derived from recombination of conventional VH gene segments with heavy-chain constant gene segments during B cell maturation. This was confirmed by the absence of the CH1 domain when such VHH domains were reisolated from the original immune repertoire using a CDR3-specific primer (De Haard, unpublished observation). Therefore, we refer to these as conventional-like VHH domains. Although the increased hydrophilicity of VHHs predominantly relies on the aforementioned changes in the former VL interface, some amino acids at positions that form a slightly hydrophobic patch on conventional VH domains that contacts CH1 (Lesk and Chothia <xref ref-type="bibr" rid="CR47">1988</xref>) are also changed into hydrophilic residues in VHHs (Muyldermans et al. <xref ref-type="bibr" rid="CR50">1994</xref>; Harmsen et al. <xref ref-type="bibr" rid="CR32">2000</xref>).</p>
      <p>Furthermore, the CDRs of VHHs contain some characteristic features. Firstly, the N-terminal part of CDR1 is more variable (Vu et al. <xref ref-type="bibr" rid="CR88">1997</xref>; Harmsen et al. <xref ref-type="bibr" rid="CR32">2000</xref>; Nguyen et al. <xref ref-type="bibr" rid="CR52">2000</xref>). Secondly, many dromedary VHHs have an extended CDR3 that is often stabilized by an additional disulfide bond with a cysteine in CDR1 or FR2 (Muyldermans et al. <xref ref-type="bibr" rid="CR50">1994</xref>) resulting in the folding of the CDR3 loop across the former VL interface (Desmyter et al. <xref ref-type="bibr" rid="CR15">1996</xref>). A particular subfamily of llama VHHs (VHH3) also contains an extended CDR3 that is stabilized by an additional disulfide bond with a cysteine at position 50 in FR2. However, VHHs of this subfamily are rarely isolated, and most llama VHHs have CDR3 loops similar in length to those found in human VHs.</p>
      <p>VHHs have many advantages for biotechnological applications, which are summarized in Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>. An important advantage is their high microbial production level (see next section).
<table-wrap id="Tab1"><label>Table&#xA0;1</label><caption><p>Advantages of camelid single-domain antibody fragments as compared to conventional antibody fragments</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Advantage</th><th>Molecular basis</th></tr></thead><tbody><tr><td>Facile genetic manipulation</td><td>Single-domain nature</td></tr><tr><td>Increased functional size of immune libraries</td><td>No decrease in library size because of reshuffling of VL and VH domains</td></tr><tr><td>Facile production of multivalent formats</td><td>More flexible linker design and no mispairing of VL and VH domains</td></tr><tr><td>Facile production of oligoclonal preparations from single cells</td><td>No mispairing of VL and VH domains</td></tr><tr><td>High physicochemical stability</td><td>Efficient refolding due to increased hydrophilicity and single-domain nature</td></tr><tr><td>High solubility</td><td>Increased hydrophilicity</td></tr><tr><td>Recognition of hidden antigenic sites</td><td>Small size and extended flexible CDR3</td></tr><tr><td>Rapid tissue penetration, fast clearance</td><td>Small size</td></tr><tr><td>Well expressed</td><td>Efficient folding due to increased hydrophilicity and single-domain nature</td></tr></tbody></table><table-wrap-foot><p>See text for references</p></table-wrap-foot></table-wrap></p>
      <p>Several advantages result from their single domain nature. Thus, VHH libraries generated from immunized camelids retain full functional diversity. This contrasts with the diminished diversity of conventional antibody libraries because of reshuffling of VL and VH domains during library construction. As a result, high-affinity antigen-binding VHHs can be isolated by directly screening a limited number of clones from immune libraries without prior selection using display technologies (Frenken et al. <xref ref-type="bibr" rid="CR24">2000</xref>; Harmsen et al. <xref ref-type="bibr" rid="CR34">2005b</xref>). Furthermore, the single-domain nature facilitates subsequent molecular manipulation. For example, for many applications, it is advantageous to engineer monovalent antibody fragments into multivalent formats to increase functional affinity (termed avidity) or to produce bispecific antibody fragments that can simultaneously bind to different antigens. Such molecules (diabodies, Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>a) can be produced using conventional recombinant antibodies using linkers between the VH and VL domains of a specific length, although this often results in aggregation and reduced affinity because of mispairing of VH and VL domains (Glockshuber et al. <xref ref-type="bibr" rid="CR26">1990</xref>; Whitlow et al. <xref ref-type="bibr" rid="CR90">1993</xref>). VHHs are more suitable for production of such formats because they allow more flexible linker design, which is important for simultaneous binding of multivalent antigens, without the problems posed by domain mispairing. Thus, several functional trivalent-bispecific VHHs have been successfully produced (Coppieters et al. <xref ref-type="bibr" rid="CR9">2006</xref>; Roovers et al. <xref ref-type="bibr" rid="CR65">2007</xref>).</p>
      <p>The use of mixtures of a limited number of monoclonal antibodies (oligoclonal antibodies) is advantageous over single monoclonal antibodies for particular applications, such as toxin neutralization (Nowakowski et al. <xref ref-type="bibr" rid="CR55">2002</xref>). Because of regulatory requirements, such oligoclonals are preferentially produced from single cells. Again, VHHs are predicted to be more suitable for single-cell production of oligoclonals because of the absence of domain mispairing, although this is yet to be demonstrated experimentally.</p>
      <p>Contrary to conventional antibodies, VHHs have been shown to remain functional at 90&#xB0;C (Van der Linden et al. <xref ref-type="bibr" rid="CR81">1999</xref>) or after incubation at high temperatures (Van der Linden et al. <xref ref-type="bibr" rid="CR81">1999</xref>; Perez et al. <xref ref-type="bibr" rid="CR58">2001</xref>). This high apparent stability is mainly attributed to their efficient refolding after chemical or thermal denaturation and to a lesser extent because of an increased resistance against denaturation (Perez et al. <xref ref-type="bibr" rid="CR58">2001</xref>; Dumoulin et al. <xref ref-type="bibr" rid="CR19">2002</xref>; Ewert et al. <xref ref-type="bibr" rid="CR23">2002</xref>). The increased apparent stability is probably due to an increased hydrophilicity of the former VL interface region because a &#x201C;camelized&#x201D; human VH fragment that contains several of the hallmark hydrophilic amino acid residues of VHHs was more stable than the original VH fragment (Davies and Riechmann <xref ref-type="bibr" rid="CR12">1995</xref>, <xref ref-type="bibr" rid="CR13">1996</xref>), whereas &#x201C;decamelization&#x201D; of a VHH to mimic a VH domain reduces its thermodynamic stability (Conrath et al. <xref ref-type="bibr" rid="CR8">2005</xref>). In addition to these specific mutations, the packing of extended CDR3 loops against this former VL interface contributes to domain stability (Bond et al. <xref ref-type="bibr" rid="CR5">2003</xref>). Furthermore, refolding of VHHs only requires domain refolding, whereas conventional antibodies also require association of VH and VL domains.</p>
      <p>VHHs can also recognize antigenic sites that are normally not recognized by conventional antibodies such as enzyme active sites (Lauwereys et al. <xref ref-type="bibr" rid="CR46">1998</xref>; De Genst et al. <xref ref-type="bibr" rid="CR14">2006</xref>) and conserved cryptic epitopes (Stijlemans et al. <xref ref-type="bibr" rid="CR73">2004</xref>). This facilitates their use as enzyme inhibitors or in diagnosis of trypanosome infections. The ability to recognize these recessed antigenic sites has been attributed to their smaller size and the ability of the extended CDR3 loop to penetrate into such sites (Desmyter et al. <xref ref-type="bibr" rid="CR15">1996</xref>; De Genst et al. <xref ref-type="bibr" rid="CR14">2006</xref>). It is interesting to note that this structure&#x2013;function relation is also observed in a rare example of a broadly reactive human mAb that recognizes the recessed and conserved CD4-binding cavity of human immunodeficiency virus type 1 gp120 by virtue of an extended CDR3 (Zwick et al. <xref ref-type="bibr" rid="CR94">2003</xref>). With respect to antigen binding, the single-domain nature could be a disadvantage for binding to small antigens such as haptens and peptides because these normally bind in a groove or cavity at the VH&#x2013;VL interface (Sundberg and Mariuzza <xref ref-type="bibr" rid="CR75">2002</xref>). Indeed, llamas immunized with clenbuterol developed conventional but not heavy-chain antibodies against this hapten (Lange et al. <xref ref-type="bibr" rid="CR45">2001</xref>). However, hapten- and peptide-binding VHHs have been successfully isolated using strong selection systems (Spinelli et al. <xref ref-type="bibr" rid="CR72">2000</xref>; Yau et al. <xref ref-type="bibr" rid="CR91">2003</xref>; Alvarez-Rueda et al. <xref ref-type="bibr" rid="CR1">2007</xref>; Harmsen et al. <xref ref-type="bibr" rid="CR36">2007</xref>). The affinities of VHHs are generally comparable to those of conventional antibody fragments (Muyldermans et al. <xref ref-type="bibr" rid="CR51">2001</xref>). Occasionally, VHHs with affinity constants (<italic>K</italic><sub>D</sub>) as low as 100&#xA0;pM are isolated (Saerens et al. <xref ref-type="bibr" rid="CR67">2004</xref>; De Genst et al. <xref ref-type="bibr" rid="CR14">2006</xref>; Harmsen et al. <xref ref-type="bibr" rid="CR35">2006</xref>), which equals the affinity ceiling proposed for natural antibodies (Sundberg and Mariuzza <xref ref-type="bibr" rid="CR75">2002</xref>).</p>
      <p>Because of their small size of about 15&#xA0;kDa, VHHs rapidly pass the renal filter, which has a cutoff of about 60&#xA0;kDa, resulting in their rapid blood clearance. In addition, the small size results in a fast tissue penetration. This is advantageous for targeting of VHHs coupled to toxic substances to tumors (Cortez-Retamozo et al. <xref ref-type="bibr" rid="CR11">2004</xref>), in vivo diagnosis using imaging, and treatment of snake bites (Harrison et al. <xref ref-type="bibr" rid="CR37">2006</xref>). However, for other therapeutic applications, such as treatment of infectious or inflammatory diseases, the short serum half-life of about 2&#xA0;h (Cortez-Retamozo et al. <xref ref-type="bibr" rid="CR10">2002</xref>; Harmsen et al. <xref ref-type="bibr" rid="CR33">2005a</xref>) is a disadvantage.</p>
    </sec>
    <sec id="Sec3">
      <title>Production in microorganisms</title>
      <p>Although a fully active nonglycosylated IgG was recently produced at high level in <italic>Escherichia coli</italic>, most functional complete antibodies can only be efficiently produced using mammalian cells, especially when their appropriate glycosylation is required for therapeutic applications. However, antibody fragments that lack the Fc with its N-linked oligosaccharide are preferably produced in microbial systems (Arbabi-Ghahroudi et al. <xref ref-type="bibr" rid="CR3">2005</xref>). These have a shorter development time from gene to product and require simple well-established fermentation conditions that can be performed on large-scale resulting in costs of goods that can be as low as $1 per gram heterologous protein (Estell <xref ref-type="bibr" rid="CR22">2006</xref>). Most large-scale microbial production systems are based on <italic>E. coli</italic>, yeasts, or filamentous fungi. Production in <italic>E. coli</italic> can be done by secretion into the oxidizing periplasmic space or expression in the reducing cytosol. The latter requires the often cumbersome refolding of antibody fragments (Arbabi-Ghahroudi et al. <xref ref-type="bibr" rid="CR3">2005</xref>). Using eukaryotic microbial hosts, antibody fragments are generally produced by targeting to the secretory pathway. This enables efficient disulfide bond formation, addition of N-linked oligosaccharide, and secretion of soluble, correctly folded product to the culture medium.</p>
      <p>VHHs have often been produced in <italic>E. coli</italic> (Arbabi-Ghahroudi et al. <xref ref-type="bibr" rid="CR2">1997</xref>; Rahbarizadeh et al. <xref ref-type="bibr" rid="CR61">2005</xref>). There is only one example of VHH production in filamentous fungi, which resulted in limited proteolytic degradation of the secreted product (Joosten et al. <xref ref-type="bibr" rid="CR43">2005</xref>) because of the high levels of proteases secreted by filamentous fungi (Gerngross <xref ref-type="bibr" rid="CR25">2004</xref>). VHHs have also often been produced in the yeast <italic>Saccharomyces cerevisiae</italic> (Frenken et al. <xref ref-type="bibr" rid="CR24">2000</xref>; Thomassen et al. <xref ref-type="bibr" rid="CR77">2002</xref>; Van der Vaart <xref ref-type="bibr" rid="CR84">2002</xref>). VHH production by the favored yeast expression host <italic>Pichia pastoris</italic> was only recently described (Rahbarizadeh et al. <xref ref-type="bibr" rid="CR62">2006</xref>). Occasionally, yeast-produced VHHs are N-glycosylated (Frenken et al. <xref ref-type="bibr" rid="CR24">2000</xref>; Harmsen et al. <xref ref-type="bibr" rid="CR33">2005a</xref>). This can affect antigen binding (Van der Vaart et al. <xref ref-type="bibr" rid="CR85">2006</xref>). Furthermore, it could complicate their therapeutic use because the addition of yeast-specific high-mannose oligosaccharides results in a high immunogenicity and decreased serum half-life because of binding to specific mannose receptors on cells of the reticulo-endothelial system (Sethuraman and Stadheim <xref ref-type="bibr" rid="CR69">2006</xref>).</p>
      <p>Although VHHs are generally well produced in microorganisms, the production level of different clones can vary by a factor of 100 (Frenken et al. <xref ref-type="bibr" rid="CR24">2000</xref>; Harmsen et al. <xref ref-type="bibr" rid="CR34">2005b</xref>; Van de Laar et al. <xref ref-type="bibr" rid="CR80">2007</xref>). Several VHH sequence patterns can be associated with their production level. First, the presence of a potential N-linked glycosylation site often increases production levels in yeast (Sagt et al. <xref ref-type="bibr" rid="CR68">2000</xref>). Second, in our experience (Harmsen, unpublished observations), conventional-like VHHs are generally produced at reduced levels in yeast. This contrasts with the reported efficient production in <italic>E. coli</italic> of VHH-like VHs (Tanha et al. <xref ref-type="bibr" rid="CR76">2002</xref>) but is consistent with the increased production level of &#x201C;camelized&#x201D; conventional VH domains in <italic>E. coli</italic> (Davies and Riechmann <xref ref-type="bibr" rid="CR12">1995</xref>). Third, the presence of unpaired C-terminal cysteines reduces expression levels (Simmons et al. <xref ref-type="bibr" rid="CR70">2006</xref>). Fourth, replacement of hydrophobic residues of conventional VH domains normally interacting with CH1 increased scFv production in <italic>E. coli</italic> (Nieba et al. <xref ref-type="bibr" rid="CR54">1997</xref>), suggesting that the hydrophilic mutations that naturally occur at these positions in VHHs also contributes to their high expression level. However, there are many examples of VHHs that differ by only a few amino acids and are produced at highly variable levels where the exact amino acid change responsible for the difference in production level is difficult to predict (Frenken et al. <xref ref-type="bibr" rid="CR24">2000</xref>; Harmsen et al. <xref ref-type="bibr" rid="CR34">2005b</xref>). Furthermore, without such knowledge, VHH production can be improved by random molecular evolution using deoxyribonucleic acid shuffling (Van der Linden et al. <xref ref-type="bibr" rid="CR83">2000b</xref>), as has often been done for conventional antibody fragments (Dufner et al. <xref ref-type="bibr" rid="CR18">2006</xref>). The high refolding capability of VHHs, which is a consequence of their sequence, has also been correlated with a high production level in <italic>E. coli</italic> (Jespers et al. <xref ref-type="bibr" rid="CR42">2004</xref>; Olichon et al. <xref ref-type="bibr" rid="CR56">2007</xref>).</p>
      <p>In addition to the nature of the VHH, host factors affecting VHH production have been identified. In baker&#x2019;s yeast, the specific VHH production rate is correlated with growth rate (Thomassen et al. <xref ref-type="bibr" rid="CR78">2005</xref>) and can be up to fivefold increased by growing on ethanol as the carbon source (Van de Laar et al. <xref ref-type="bibr" rid="CR80">2007</xref>). Supplementation of the medium with sorbitol, casamino acids, or ethylenediamine tetraacetic acid improves VHH production by <italic>P. pastoris</italic> (Rahbarizadeh et al. <xref ref-type="bibr" rid="CR62">2006</xref>).</p>
      <p>In addition to monovalent VHHs, several expression formats for the production of VHH multimers have been described (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>b). These include genetic fusions of two (Conrath et al. <xref ref-type="bibr" rid="CR7">2001b</xref>; Harmsen et al. <xref ref-type="bibr" rid="CR33">2005a</xref>) or three VHHs (Coppieters et al. <xref ref-type="bibr" rid="CR9">2006</xref>; Roovers et al. <xref ref-type="bibr" rid="CR65">2007</xref>) that either recognize different antigens or the same repeating antigen to increase functional affinity. Although such VHH fusions are less efficiently produced than their monovalent versions, their production level exceeds that of their conventional-antibody-based fusion counterparts without aggregation or low solubility. However, antigen binding by the C-terminal VHH in such fusions can be compromised (Conrath et al. <xref ref-type="bibr" rid="CR7">2001b</xref>) presumably because of steric hindrance by the N-terminal VHH. The avidity of VHHs has also been strongly increased using genetic fusions to the B-subunits of an <italic>E. coli</italic> toxin that self-assembles into a homopentamer (Zhang et al. <xref ref-type="bibr" rid="CR93">2004</xref>), resulting in pentameric recombinant antibodies (&#x201C;pentabodies,&#x201D; Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>b).</p>
      <p>VHHs on their own cannot recruit effector functions such as ADCC and CDC. This limits their therapeutic application. Although such effector functions can be indirectly recruited using bispecific (conventional) antibody fragments binding to host immunoglobulin (Holliger et al. <xref ref-type="bibr" rid="CR40">1997</xref>), it may be more efficient to recruit these functions by fusing VHHs to host Fc domains. Production of such functional antibodies requires the correct glycosylation of the CH2 domain, which until recently could only be accomplished using higher eukaryotic cells (Nguyen et al. <xref ref-type="bibr" rid="CR53">2003</xref>) but not by microbial production. However, this may now be feasible using <italic>P. pastoris</italic> strains with an engineered glycosylation machinery that are able to produce proteins with a specific human glycoform (Hamilton et al. <xref ref-type="bibr" rid="CR31">2006</xref>). Furthermore, transgenic mice containing hybrid llama/human antibody loci that contain llama V regions and human D, J, and C regions have recently been used to generate human heavy-chain antibodies in mice (Janssens et al. <xref ref-type="bibr" rid="CR41">2006</xref>).</p>
    </sec>
    <sec id="Sec4">
      <title>Therapeutic applications</title>
      <p>Although VHHs are highly suited for applications that require a high stability, such as use in shampoo for the prevention of dandruff (Dolk et al. <xref ref-type="bibr" rid="CR17">2005</xref>), as capturing reagents in immunoaffinity purification (Verheesen et al. <xref ref-type="bibr" rid="CR86">2003</xref>), or use in biosensors (Pleschberger et al. <xref ref-type="bibr" rid="CR59">2004</xref>), we would like to focus on their therapeutic applications, which are more challenging. Several VHHs are now being studied for use in various disease areas, including oncology (Revets et al. <xref ref-type="bibr" rid="CR64">2005</xref>) and in infectious, inflammatory, and neurodegenerative diseases (Table&#xA0;<xref rid="Tab2" ref-type="table">2</xref>).
<table-wrap id="Tab2"><label>Table&#xA0;2</label><caption><p>Examples of therapeutic applications of camelid VHHs</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Disease</th><th>Pathogen</th><th>Target antigen</th><th>VHH valency for disease target</th><th>Additional fusion partner</th><th>Reference</th></tr></thead><tbody><tr><td>Sleeping sickness</td><td>Trypanosomes</td><td>VSG oligomannose</td><td>Monovalent</td><td>Apolipoprotein L-I</td><td>Baral et al. <xref ref-type="bibr" rid="CR4">2006</xref></td></tr><tr><td>Infant diarrhea</td><td>Rotavirus</td><td>Unknown</td><td>Monovalent</td><td>None</td><td>Van der Vaart et al. <xref ref-type="bibr" rid="CR85">2006</xref></td></tr><tr><td>Infant diarrhea</td><td>Rotavirus</td><td>Unknown</td><td>Monovalent</td><td><italic>Lactobacillus</italic> cell-surface anchor</td><td>Pant et al. <xref ref-type="bibr" rid="CR57">2006</xref></td></tr><tr><td>Piglet diarrhea</td><td><italic>E. coli</italic></td><td>F4 fimbriae</td><td>Monovalent</td><td>None</td><td>Harmsen et al. <xref ref-type="bibr" rid="CR35">2006</xref></td></tr><tr><td>Caries</td><td><italic>S. mutans</italic></td><td>I/II adhesion</td><td>Monovalent</td><td>None</td><td>Kruger et al. <xref ref-type="bibr" rid="CR44">2006</xref></td></tr><tr><td>FMD</td><td>FMD virus</td><td>VP1</td><td>Monovalent</td><td>PEG</td><td>Harmsen et al. <xref ref-type="bibr" rid="CR36">2007</xref></td></tr><tr><td>Sepsis</td><td><italic>N. meningitidis</italic></td><td>LPS</td><td>Monovalent</td><td>None</td><td>El Khattabi et al. <xref ref-type="bibr" rid="CR21">2006</xref></td></tr><tr><td>Cancer</td><td>&#x2013;</td><td>CEA</td><td>Monovalent</td><td>&#x3B2;-Lactamase</td><td>Cortez-Retamozo et al. <xref ref-type="bibr" rid="CR11">2004</xref></td></tr><tr><td>Cancer</td><td>&#x2013;</td><td>EGF receptor</td><td>Bivalent</td><td>Anti-albumin VHH</td><td>Roovers et al. <xref ref-type="bibr" rid="CR65">2007</xref></td></tr><tr><td>Rheumatoid arthritis</td><td>&#x2013;</td><td>TNF&#x3B1;</td><td>Bivalent</td><td>Anti-albumin VHH</td><td>Coppieters et al. <xref ref-type="bibr" rid="CR9">2006</xref></td></tr><tr><td>Brain disorders</td><td>&#x2013;</td><td>&#x3B1; (2,3)-Sialoglycoprotein</td><td>Monovalent</td><td>None</td><td>Muruganandam et al. <xref ref-type="bibr" rid="CR48">2002</xref></td></tr><tr><td>Neurodegenerative diseases</td><td>&#x2013;</td><td>Bax</td><td>Monovalent</td><td>None</td><td>Gueorguieva et al. <xref ref-type="bibr" rid="CR29">2006</xref></td></tr></tbody></table></table-wrap></p>
      <p>VHHs are especially suited for oral immunotherapy because of their resistance against extremes of pH and the capacity to bind to the target at high concentrations of chaotropic agents (Dumoulin et al. <xref ref-type="bibr" rid="CR19">2002</xref>, <xref ref-type="bibr" rid="CR20">2003</xref>). Administration to piglets of a VHH that effectively prevents intestinal attachment of <italic>E. coli</italic> bacteria that cause diarrhea resulted in poor in vivo protection (Harmsen et al. <xref ref-type="bibr" rid="CR34">2005b</xref>) because of degradation by gastrointestinal proteases (Harmsen et al. <xref ref-type="bibr" rid="CR35">2006</xref>). However, by selection for proteolytic stability, a VHH could be isolated from the original library that was not degraded in vivo (Harmsen et al. <xref ref-type="bibr" rid="CR35">2006</xref>). VHHs that successfully prevented diarrhea caused by rotavirus in a mouse model were similarly selected for resistance against the acidic environment of the stomach (Van der Vaart et al. <xref ref-type="bibr" rid="CR85">2006</xref>). Alternatively, VHH proteolysis can be prevented by local VHH production using natural gut commensal bacteria. Thus, diarrhea could also be prevented by lactobacilli that produce rotavirus-neutralizing VHHs fused to a cell surface anchor (Pant et al. <xref ref-type="bibr" rid="CR57">2006</xref>). Treatment of caries, caused by <italic>Streptococcus mutans</italic>, with VHHs conferred only limited protection (Kruger et al. <xref ref-type="bibr" rid="CR44">2006</xref>). Because these VHHs should function in the oral cavity, the low level of protection cannot be due to proteolytic VHH degradation within the gastrointestinal tract.</p>
      <p>The short serum half-life because of a rapid renal clearance limits the efficacy of VHHs in many parenteral applications. Therefore, VHHs have been targeted to normally long-lived serum proteins such as albumin (Coppieters et al. <xref ref-type="bibr" rid="CR9">2006</xref>; Roovers et al. <xref ref-type="bibr" rid="CR65">2007</xref>) or immunoglobulin (Harmsen et al. <xref ref-type="bibr" rid="CR33">2005a</xref>) using bispecific VHHs recognizing these serum proteins in addition to the therapeutic target, resulting in half-lives that equal the half-life of albumin (2&#xA0;days in mice) and immunoglobulin (9&#xA0;days). An alternative well-known approach to increase serum half-life of proteins is the chemical addition of polyethylene glycol (PEG). Such PEGylation of foot-and-mouth disease (FMD) virus-neutralizing VHHs not only increased serum half-life but also increased in vitro neutralizing potency to levels above that of the hyperimmune serum (Harmsen et al. <xref ref-type="bibr" rid="CR36">2007</xref>). However, in contrast to the full protection afforded by the hyperimmune serum, these VHHs poorly protected guinea pigs from FMD viral challenge infection, suggesting that Fc-mediated effector functions are required for efficient in vivo protection (Harmsen et al. <xref ref-type="bibr" rid="CR36">2007</xref>).</p>
      <p>Nevertheless, many diseases were successfully treated with VHHs in the absence of Fc-mediated effector functions. These VHHs either are used as targeting devices for toxic enzymes or block a specific molecular interaction. For example, sleeping sickness was successfully treated with VHHs that bind to a trypanosome coat protein and were fused to the apolipoprotein L-1 enzyme, resulting in trypanosome lysis (Baral et al. <xref ref-type="bibr" rid="CR4">2006</xref>). In oncology, a VHH directed against carcinoembryonic antigen was used for targeting the genetically fused &#x3B2;-lactamase to tumor cells. This enzyme then converts an injected nontoxic prodrug into a toxic drug in the vicinity of the targeted tumor cells, leading to their killing (Cortez-Retamozo et al. <xref ref-type="bibr" rid="CR11">2004</xref>). Several VHH therapies are also being developed for treatment of oncology or inflammatory diseases based on blocking molecular interactions. VHHs binding to epidermal growth factor receptor (EGFR) can block epidermal growth factor (EGF) binding to its receptor, which can be used to treat solid tumors (Roovers et al. <xref ref-type="bibr" rid="CR65">2007</xref>). Tenfold more potent EGFR-binding VHHs could be obtained by construction of bivalent formats. It is interesting to note that the recently approved conventional antibody Panitumumab directed against EGFR also blocks EGF binding and is expected to give poor ADCC and CDC (Reichert and Valge-Archer <xref ref-type="bibr" rid="CR63">2007</xref>). Furthermore, by blocking receptor interaction, VHHs binding to tumor necrosis factor-&#x3B1; can be used for treatment of rheumatoid arthritis (Coppieters et al. <xref ref-type="bibr" rid="CR9">2006</xref>). The potency of bivalent formats was 500-fold increased as compared to monovalent VHHs and even exceeded the potency of clinically used conventional antibodies both in vitro and in a murine arthritis model. Similarly, lipopolysaccharide (LPS)-binding VHHs were isolated that block LPS binding and signaling to host cells for treatment of sepsis (El Khattabi et al. <xref ref-type="bibr" rid="CR21">2006</xref>).</p>
      <p>The potential immunogenicity of VHHs could compromise their parenteral therapeutic use, especially in treatments that require repeated injections. Until now, multiple injections of VHHs have not shown any immunogenicity in mice, as assessed by the presence of specific antibodies, T cell proliferation, or cytokine levels (Cortez-Retamozo et al. <xref ref-type="bibr" rid="CR10">2002</xref>; Coppieters et al. <xref ref-type="bibr" rid="CR9">2006</xref>). This could rely on their high sequence homology to conventional VH domains and on their high stability because aggregation of proteins is known to increase immunogenicity (Hermeling et al. <xref ref-type="bibr" rid="CR38">2004</xref>). If necessary, technologies developed to decrease immunogenicity of mouse monoclonal antibodies (Presta <xref ref-type="bibr" rid="CR60">2006</xref>) could also be applied to VHHs. Alternatively, immunogenicity could be reduced by the use of conventional-like VHHs, which have an even higher structural homology to conventional VH domains.</p>
      <p>For their use in targeting drugs across the blood&#x2013;brain barrier (BBB) into the brain, VHHs were selected that transmigrate the human BBB in an in vitro model and accumulate in the brain after intravenous injection into mice (Muruganandam et al. <xref ref-type="bibr" rid="CR48">2002</xref>). These could be used for treatment of neurological disorders. Finally, Bax-specific VHHs have been expressed in the cytoplasm, resulting in so-called intrabodies, to prevent oxidative-stress-induced apoptosis that is implicated in several neurodegenerative diseases (Gueorguieva et al. <xref ref-type="bibr" rid="CR29">2006</xref>). Because of their stability, VHHs are especially suited for intrabody production because this requires expression in the reducing environment of the cytoplasm (Gueorguieva et al. <xref ref-type="bibr" rid="CR29">2006</xref>; Rothbauer et al. <xref ref-type="bibr" rid="CR66">2006</xref>).</p>
    </sec>
    <sec id="Sec5" sec-type="conclusion">
      <title>Conclusions</title>
      <p>Since the discovery of heavy-chain antibodies in 1993, the field of single-domain antibody fragments has been rapidly growing. VHHs have many advantages for biotechnological applications. They can be economically produced in microorganisms and have a high stability. Furthermore, they are highly suited for expression as multivalent, including bispecific, formats or as enzyme fusions. This permits a plug-and-play approach, where, depending on the target, biology potency can be increased by multivalent constructs or bispecific VHH recognizing two different targets can be made. This also enables the tailor-made design of serum half-life using site-directed PEGylation or by targeting to long-lived serum proteins using bispecific VHHs. Although fusions of targeting VHHs to Ig-binding VHHs or Fc can be used to recruit effector functions most current research on VHHs focuses on therapeutic applications where such effector functions are not required. Finally, conventional whole antibodies occasionally give side effects because of their bivalent nature, which can result in target cross-linking, or the presence of the Fc region. Evidently, such side effects are not expected to occur using monovalent VHHs. This, however, is yet to be confirmed as the first VHH has entered phase I clinical trials in 2007 (<ext-link ext-link-type="uri" xlink:href="http://www.ablynx.com">http://www.ablynx.com</ext-link>).</p>
    </sec>
  </body>
  <back>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Alvarez-Rueda</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Behar</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Ferre</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Pugniere</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Roquet</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Gastinel</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Jacquot</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Aubry</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Baty</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Barbet</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Birkle</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Generation of llama single-domain antibodies against methotrexate, a prototypical hapten</article-title>
          <source>Mol Immunol</source>
          <year>2007</year>
          <volume>44</volume>
          <fpage>1680</fpage>
          <lpage>1690</lpage>
          <pub-id pub-id-type="doi">10.1016/j.molimm.2006.08.007</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Alvarez-Rueda N, Behar G, Ferre V, Pugniere M, Roquet F, Gastinel L, Jacquot C, Aubry J, Baty D, Barbet J, Birkle S (2007) Generation of llama single-domain antibodies against methotrexate, a prototypical hapten. Mol Immunol 44:1680&#x2013;1690 <pub-id pub-id-type="pmid">17011035</pub-id></citation>
      </ref>
      <ref id="CR2">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Arbabi-Ghahroudi</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Desmyter</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Wyns</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Hamers</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Muyldermans</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Selection and identification of single domain antibody fragments from camel heavy-chain antibodies</article-title>
          <source>FEBS Lett</source>
          <year>1997</year>
          <volume>414</volume>
          <fpage>521</fpage>
          <lpage>526</lpage>
          <pub-id pub-id-type="doi">10.1016/S0014-5793(97)01062-4</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Arbabi-Ghahroudi M, Desmyter A, Wyns L, Hamers R, Muyldermans S (1997) Selection and identification of single domain antibody fragments from camel heavy-chain antibodies. FEBS Lett 414:521&#x2013;526 <pub-id pub-id-type="pmid">9323027</pub-id></citation>
      </ref>
      <ref id="CR3">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Arbabi-Ghahroudi</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Tanha</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>MacKenzie</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Prokaryotic expression of antibodies</article-title>
          <source>Cancer Metastasis Rev</source>
          <year>2005</year>
          <volume>24</volume>
          <fpage>501</fpage>
          <lpage>519</lpage>
          <pub-id pub-id-type="doi">10.1007/s10555-005-6193-1</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Arbabi-Ghahroudi M, Tanha J, MacKenzie R (2005) Prokaryotic expression of antibodies. Cancer Metastasis Rev 24:501&#x2013;519 <pub-id pub-id-type="pmid">16408159</pub-id></citation>
      </ref>
      <ref id="CR4">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Baral</surname>
              <given-names>TN</given-names>
            </name>
            <name>
              <surname>Magez</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Stijlemans</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Conrath</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Vanhollebeke</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Pays</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Muyldermans</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Baetselier</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Experimental therapy of African trypanosomiasis with a nanobody-conjugated human trypanolytic factor</article-title>
          <source>Nat Med</source>
          <year>2006</year>
          <volume>12</volume>
          <fpage>580</fpage>
          <lpage>584</lpage>
          <pub-id pub-id-type="doi">10.1038/nm1395</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Baral TN, Magez S, Stijlemans B, Conrath K, Vanhollebeke B, Pays E, Muyldermans S, De Baetselier P (2006) Experimental therapy of African trypanosomiasis with a nanobody-conjugated human trypanolytic factor. Nat Med 12:580&#x2013;584 <pub-id pub-id-type="pmid">16604085</pub-id></citation>
      </ref>
      <ref id="CR5">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bond</surname>
              <given-names>CJ</given-names>
            </name>
            <name>
              <surname>Marsters</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Sidhu</surname>
              <given-names>SS</given-names>
            </name>
          </person-group>
          <article-title>Contributions of CDR3 to VHH domain stability and the design of monobody scaffolds for naive antibody libraries</article-title>
          <source>J Mol Biol</source>
          <year>2003</year>
          <volume>332</volume>
          <fpage>643</fpage>
          <lpage>655</lpage>
          <pub-id pub-id-type="doi">10.1016/S0022-2836(03)00967-7</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Bond CJ, Marsters JC, Sidhu SS (2003) Contributions of CDR3 to VHH domain stability and the design of monobody scaffolds for naive antibody libraries. J Mol Biol 332:643&#x2013;655 <pub-id pub-id-type="pmid">12963373</pub-id></citation>
      </ref>
      <ref id="CR6">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Conrath</surname>
              <given-names>KE</given-names>
            </name>
            <name>
              <surname>Lauwereys</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Galleni</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Matagne</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Frere</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Kinne</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Wyns</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Muyldermans</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Beta-lactamase inhibitors derived from single-domain antibody fragments elicited in the camelidae</article-title>
          <source>Antimicrob Agents Chemother</source>
          <year>2001</year>
          <volume>45</volume>
          <fpage>2807</fpage>
          <lpage>2812</lpage>
          <pub-id pub-id-type="doi">10.1128/AAC.45.10.2807-2812.2001</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Conrath KE, Lauwereys M, Galleni M, Matagne A, Frere JM, Kinne J, Wyns L, Muyldermans S (2001a) Beta-lactamase inhibitors derived from single-domain antibody fragments elicited in the camelidae. Antimicrob Agents Chemother 45:2807&#x2013;2812 <pub-id pub-id-type="pmid">11557473</pub-id></citation>
      </ref>
      <ref id="CR7">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Conrath</surname>
              <given-names>KE</given-names>
            </name>
            <name>
              <surname>Lauwereys</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Wyns</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Muyldermans</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Camel single-domain antibodies as modular building units in bispecific and bivalent antibody constructs</article-title>
          <source>J Biol Chem</source>
          <year>2001</year>
          <volume>276</volume>
          <fpage>7346</fpage>
          <lpage>7350</lpage>
          <pub-id pub-id-type="doi">10.1074/jbc.M007734200</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Conrath KE, Lauwereys M, Wyns L, Muyldermans S (2001b) Camel single-domain antibodies as modular building units in bispecific and bivalent antibody constructs. J Biol Chem 276:7346&#x2013;7350 <pub-id pub-id-type="pmid">11053416</pub-id></citation>
      </ref>
      <ref id="CR8">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Conrath</surname>
              <given-names>KE</given-names>
            </name>
            <name>
              <surname>Vincke</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Stijlemans</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Schymkowitz</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Decanniere</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Wyns</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Muyldermans</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Loris</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Antigen binding and solubility effects upon the veneering of a camel VHH in framework-2 to mimic a VH</article-title>
          <source>J Mol Biol</source>
          <year>2005</year>
          <volume>350</volume>
          <fpage>112</fpage>
          <lpage>125</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jmb.2005.04.050</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Conrath KE, Vincke C, Stijlemans B, Schymkowitz J, Decanniere K, Wyns L, Muyldermans S, Loris R (2005) Antigen binding and solubility effects upon the veneering of a camel VHH in framework-2 to mimic a VH. J Mol Biol 350:112&#x2013;125 <pub-id pub-id-type="pmid">15913651</pub-id></citation>
      </ref>
      <ref id="CR9">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Coppieters</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Dreier</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Silence</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Haard</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Lauwereys</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Casteels</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Beirnaert</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Jonckheere</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Wiele</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Staelens</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Hostens</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Revets</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Remaut</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Elewaut</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Rottiers</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <article-title>Formatted anti-tumor necrosis factor alpha VHH proteins derived from camelids show superior potency and targeting to inflamed joints in a murine model of collagen-induced arthritis</article-title>
          <source>Arthritis Rheum</source>
          <year>2006</year>
          <volume>54</volume>
          <fpage>1856</fpage>
          <lpage>1866</lpage>
          <pub-id pub-id-type="doi">10.1002/art.21827</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Coppieters K, Dreier T, Silence K, de Haard H, Lauwereys M, Casteels P, Beirnaert E, Jonckheere H, Van de Wiele C, Staelens L, Hostens J, Revets H, Remaut E, Elewaut D, Rottiers P (2006) Formatted anti-tumor necrosis factor alpha VHH proteins derived from camelids show superior potency and targeting to inflamed joints in a murine model of collagen-induced arthritis. Arthritis Rheum 54:1856&#x2013;1866 <pub-id pub-id-type="pmid">16736523</pub-id></citation>
      </ref>
      <ref id="CR10">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cortez-Retamozo</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Lauwereys</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Hassanzadeh Gh</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Gobert</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Conrath</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Muyldermans</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Baetselier</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Revets</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Efficient tumor targeting by single-domain antibody fragments of camels</article-title>
          <source>Int J Cancer</source>
          <year>2002</year>
          <volume>98</volume>
          <fpage>456</fpage>
          <lpage>462</lpage>
          <pub-id pub-id-type="doi">10.1002/ijc.10212</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Cortez-Retamozo V, Lauwereys M, Hassanzadeh Gh G, Gobert M, Conrath K, Muyldermans S, De Baetselier P, Revets H (2002) Efficient tumor targeting by single-domain antibody fragments of camels. Int J Cancer 98:456&#x2013;462 <pub-id pub-id-type="pmid">11920600</pub-id></citation>
      </ref>
      <ref id="CR11">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cortez-Retamozo</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Backmann</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Senter</surname>
              <given-names>PD</given-names>
            </name>
            <name>
              <surname>Wernery</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Baetselier</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Muyldermans</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Revets</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Efficient cancer therapy with a nanobody-based conjugate</article-title>
          <source>Cancer Res</source>
          <year>2004</year>
          <volume>64</volume>
          <fpage>2853</fpage>
          <lpage>2857</lpage>
          <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-03-3935</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Cortez-Retamozo V, Backmann N, Senter PD, Wernery U, De Baetselier P, Muyldermans S, Revets H (2004) Efficient cancer therapy with a nanobody-based conjugate. Cancer Res 64:2853&#x2013;2857 <pub-id pub-id-type="pmid">15087403</pub-id></citation>
      </ref>
      <ref id="CR12">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Davies</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Riechmann</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
          <article-title>Antibody VH domains as small recognition units</article-title>
          <source>Biotechnology (NY)</source>
          <year>1995</year>
          <volume>13</volume>
          <fpage>475</fpage>
          <lpage>479</lpage>
          <pub-id pub-id-type="doi">10.1038/nbt0595-475</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Davies J, Riechmann L (1995) Antibody VH domains as small recognition units. Biotechnology (NY) 13:475&#x2013;479 </citation>
      </ref>
      <ref id="CR13">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Davies</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Riechmann</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
          <article-title>Single antibody domains as small recognition units: design and in vitro antigen selection of camelized, human VH domains with improved protein stability</article-title>
          <source>Protein Eng</source>
          <year>1996</year>
          <volume>9</volume>
          <fpage>531</fpage>
          <lpage>537</lpage>
          <pub-id pub-id-type="doi">10.1093/protein/9.6.531</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Davies J, Riechmann L (1996) Single antibody domains as small recognition units: design and in vitro antigen selection of camelized, human VH domains with improved protein stability. Protein Eng 9:531&#x2013;537 <pub-id pub-id-type="pmid">8862554</pub-id></citation>
      </ref>
      <ref id="CR14">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Genst</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Silence</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Decanniere</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Conrath</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Loris</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Kinne</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Muyldermans</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Wyns</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
          <article-title>Molecular basis for the preferential cleft recognition by dromedary heavy-chain antibodies</article-title>
          <source>Proc Natl Acad Sci USA</source>
          <year>2006</year>
          <volume>103</volume>
          <fpage>4586</fpage>
          <lpage>4591</lpage>
          <pub-id pub-id-type="doi">10.1073/pnas.0505379103</pub-id>
        </citation>
        <citation citation-type="display-unstructured">De Genst E, Silence K, Decanniere K, Conrath K, Loris R, Kinne J, Muyldermans S, Wyns L (2006) Molecular basis for the preferential cleft recognition by dromedary heavy-chain antibodies. Proc Natl Acad Sci USA 103:4586&#x2013;4591 <pub-id pub-id-type="pmid">16537393</pub-id></citation>
      </ref>
      <ref id="CR15">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Desmyter</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Transue</surname>
              <given-names>TR</given-names>
            </name>
            <name>
              <surname>Ghahroudi</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Thi</surname>
              <given-names>MH</given-names>
            </name>
            <name>
              <surname>Poortmans</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Hamers</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Muyldermans</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Wyns</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
          <article-title>Crystal structure of a camel single-domain VH antibody fragment in complex with lysozyme</article-title>
          <source>Nat Struct Biol</source>
          <year>1996</year>
          <volume>3</volume>
          <fpage>803</fpage>
          <lpage>811</lpage>
          <pub-id pub-id-type="doi">10.1038/nsb0996-803</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Desmyter A, Transue TR, Ghahroudi MA, Thi MH, Poortmans F, Hamers R, Muyldermans S, Wyns L (1996) Crystal structure of a camel single-domain VH antibody fragment in complex with lysozyme. Nat Struct Biol 3:803&#x2013;811 <pub-id pub-id-type="pmid">8784355</pub-id></citation>
      </ref>
      <ref id="CR16">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Desmyter</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Decanniere</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Muyldermans</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Wyns</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
          <article-title>Antigen specificity and high affinity binding provided by one single loop of a camel single-domain antibody</article-title>
          <source>J Biol Chem</source>
          <year>2001</year>
          <volume>276</volume>
          <fpage>26285</fpage>
          <lpage>26290</lpage>
          <pub-id pub-id-type="doi">10.1074/jbc.M102107200</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Desmyter A, Decanniere K, Muyldermans S, Wyns L (2001) Antigen specificity and high affinity binding provided by one single loop of a camel single-domain antibody. J Biol Chem 276:26285&#x2013;26290 <pub-id pub-id-type="pmid">11342547</pub-id></citation>
      </ref>
      <ref id="CR17">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dolk</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Vaart</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Lutje Hulsik</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Vriend</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Haard</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Spinelli</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Cambillau</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Frenken</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Verrips</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Isolation of llama antibody fragments for prevention of dandruff by phage display in shampoo</article-title>
          <source>Appl Environ Microbiol</source>
          <year>2005</year>
          <volume>71</volume>
          <fpage>442</fpage>
          <lpage>450</lpage>
          <pub-id pub-id-type="doi">10.1128/AEM.71.1.442-450.2005</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Dolk E, van der Vaart M, Lutje Hulsik D, Vriend G, de Haard H, Spinelli S, Cambillau C, Frenken L, Verrips T (2005) Isolation of llama antibody fragments for prevention of dandruff by phage display in shampoo. Appl Environ Microbiol 71:442&#x2013;450 <pub-id pub-id-type="pmid">15640220</pub-id></citation>
      </ref>
      <ref id="CR18">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dufner</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Jermutus</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Minter</surname>
              <given-names>RR</given-names>
            </name>
          </person-group>
          <article-title>Harnessing phage and ribosome display for antibody optimisation</article-title>
          <source>Trends Biotechnol</source>
          <year>2006</year>
          <volume>24</volume>
          <fpage>523</fpage>
          <lpage>529</lpage>
        </citation>
        <citation citation-type="display-unstructured">Dufner P, Jermutus L, Minter RR (2006) Harnessing phage and ribosome display for antibody optimisation. Trends Biotechnol 24:523&#x2013;529 <pub-id pub-id-type="pmid">17000017</pub-id></citation>
      </ref>
      <ref id="CR19">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dumoulin</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Conrath</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Meirhaeghe</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Meersman</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Heremans</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Frenken</surname>
              <given-names>LG</given-names>
            </name>
            <name>
              <surname>Muyldermans</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Wyns</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Matagne</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Single-domain antibody fragments with high conformational stability</article-title>
          <source>Protein Sci</source>
          <year>2002</year>
          <volume>11</volume>
          <fpage>500</fpage>
          <lpage>515</lpage>
          <pub-id pub-id-type="doi">10.1110/ps.34602</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Dumoulin M, Conrath K, Van Meirhaeghe A, Meersman F, Heremans K, Frenken LG, Muyldermans S, Wyns L, Matagne A (2002) Single-domain antibody fragments with high conformational stability. Protein Sci 11:500&#x2013;515 <pub-id pub-id-type="pmid">11847273</pub-id></citation>
      </ref>
      <ref id="CR20">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dumoulin</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Last</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Desmyter</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Decanniere</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Canet</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Larsson</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Spencer</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Archer</surname>
              <given-names>DB</given-names>
            </name>
            <name>
              <surname>Sasse</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Muyldermans</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Wyns</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Redfield</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Matagne</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Robinson</surname>
              <given-names>CV</given-names>
            </name>
            <name>
              <surname>Dobson</surname>
              <given-names>CM</given-names>
            </name>
          </person-group>
          <article-title>A camelid antibody fragment inhibits the formation of amyloid fibrils by human lysozyme</article-title>
          <source>Nature</source>
          <year>2003</year>
          <volume>424</volume>
          <fpage>783</fpage>
          <lpage>788</lpage>
          <pub-id pub-id-type="doi">10.1038/nature01870</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Dumoulin M, Last AM, Desmyter A, Decanniere K, Canet D, Larsson G, Spencer A, Archer DB, Sasse J, Muyldermans S, Wyns L, Redfield C, Matagne A, Robinson CV, Dobson CM (2003) A camelid antibody fragment inhibits the formation of amyloid fibrils by human lysozyme. Nature 424:783&#x2013;788 <pub-id pub-id-type="pmid">12917687</pub-id></citation>
      </ref>
      <ref id="CR21">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Khattabi</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Adams</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Heezius</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Hermans</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Detmers</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Maassen</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Ley</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Tommassen</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Verrips</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Stam</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Llama single-chain antibody that blocks lipopolysaccharide binding and signaling: prospects for therapeutic applications</article-title>
          <source>Clin Vaccine Immunol</source>
          <year>2006</year>
          <volume>13</volume>
          <fpage>1079</fpage>
          <lpage>1086</lpage>
          <pub-id pub-id-type="doi">10.1128/CVI.00107-06</pub-id>
        </citation>
        <citation citation-type="display-unstructured">El Khattabi M, Adams H, Heezius E, Hermans P, Detmers F, Maassen B, van der Ley P, Tommassen J, Verrips T, Stam J (2006) Llama single-chain antibody that blocks lipopolysaccharide binding and signaling: prospects for therapeutic applications. Clin Vaccine Immunol 13:1079&#x2013;1086 <pub-id pub-id-type="pmid">16928888</pub-id></citation>
      </ref>
      <ref id="CR22">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Estell</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>Adapting industry practices for the rapid, large-scale manufacture of pharmaceutical proteins</article-title>
          <source>Bridge</source>
          <year>2006</year>
          <volume>36</volume>
          <fpage>39</fpage>
          <lpage>44</lpage>
        </citation>
        <citation citation-type="display-unstructured">Estell D (2006) Adapting industry practices for the rapid, large-scale manufacture of pharmaceutical proteins. Bridge 36:39&#x2013;44 </citation>
      </ref>
      <ref id="CR23">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ewert</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Cambillau</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Conrath</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Pluckthun</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Biophysical properties of camelid V(HH) domains compared to those of human V(H)3 domains</article-title>
          <source>Biochemistry</source>
          <year>2002</year>
          <volume>41</volume>
          <fpage>3628</fpage>
          <lpage>3636</lpage>
          <pub-id pub-id-type="doi">10.1021/bi011239a</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Ewert S, Cambillau C, Conrath K, Pluckthun A (2002) Biophysical properties of camelid V(HH) domains compared to those of human V(H)3 domains. Biochemistry 41:3628&#x2013;3636 <pub-id pub-id-type="pmid">11888279</pub-id></citation>
      </ref>
      <ref id="CR24">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Frenken</surname>
              <given-names>LGJ</given-names>
            </name>
            <name>
              <surname>Linden</surname>
              <given-names>RH</given-names>
            </name>
            <name>
              <surname>Hermans</surname>
              <given-names>PW</given-names>
            </name>
            <name>
              <surname>Bos</surname>
              <given-names>JW</given-names>
            </name>
            <name>
              <surname>Ruuls</surname>
              <given-names>RC</given-names>
            </name>
            <name>
              <surname>Geus</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Verrips</surname>
              <given-names>CT</given-names>
            </name>
          </person-group>
          <article-title>Isolation of antigen specific llama VHH antibody fragments and their high level secretion by <italic>Saccharomyces cerevisiae</italic></article-title>
          <source>J Biotechnol</source>
          <year>2000</year>
          <volume>78</volume>
          <fpage>11</fpage>
          <lpage>21</lpage>
          <pub-id pub-id-type="doi">10.1016/S0168-1656(99)00228-X</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Frenken LGJ, van der Linden RH, Hermans PW, Bos JW, Ruuls RC, de Geus B, Verrips CT (2000) Isolation of antigen specific llama VHH antibody fragments and their high level secretion by Saccharomyces cerevisiae. J Biotechnol 78:11&#x2013;21 <pub-id pub-id-type="pmid">10702907</pub-id></citation>
      </ref>
      <ref id="CR25">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gerngross</surname>
              <given-names>TU</given-names>
            </name>
          </person-group>
          <article-title>Advances in the production of human therapeutic proteins in yeasts and filamentous fungi</article-title>
          <source>Nat Biotechnol</source>
          <year>2004</year>
          <volume>22</volume>
          <fpage>1409</fpage>
          <lpage>1414</lpage>
          <pub-id pub-id-type="doi">10.1038/nbt1028</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Gerngross TU (2004) Advances in the production of human therapeutic proteins in yeasts and filamentous fungi. Nat Biotechnol 22:1409&#x2013;1414 <pub-id pub-id-type="pmid">15529166</pub-id></citation>
      </ref>
      <ref id="CR26">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Glockshuber</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Malia</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Pfitzinger</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Pluckthun</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>A comparison of strategies to stabilize immunoglobulin Fv-fragments</article-title>
          <source>Biochemistry</source>
          <year>1990</year>
          <volume>29</volume>
          <fpage>1362</fpage>
          <lpage>1367</lpage>
          <pub-id pub-id-type="doi">10.1021/bi00458a002</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Glockshuber R, Malia M, Pfitzinger I, Pluckthun A (1990) A comparison of strategies to stabilize immunoglobulin Fv-fragments. Biochemistry 29:1362&#x2013;1367 <pub-id pub-id-type="pmid">2110478</pub-id></citation>
      </ref>
      <ref id="CR27">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Goldman</surname>
              <given-names>ER</given-names>
            </name>
            <name>
              <surname>Anderson</surname>
              <given-names>GP</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Delehanty</surname>
              <given-names>JB</given-names>
            </name>
            <name>
              <surname>Sherwood</surname>
              <given-names>LJ</given-names>
            </name>
            <name>
              <surname>Osborn</surname>
              <given-names>LE</given-names>
            </name>
            <name>
              <surname>Cummins</surname>
              <given-names>LB</given-names>
            </name>
            <name>
              <surname>Hayhurst</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Facile generation of heat-stable antiviral and antitoxin single domain antibodies from a semisynthetic llama library</article-title>
          <source>Anal Chem</source>
          <year>2006</year>
          <volume>78</volume>
          <fpage>8245</fpage>
          <lpage>8255</lpage>
          <pub-id pub-id-type="doi">10.1021/ac0610053</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Goldman ER, Anderson GP, Liu JL, Delehanty JB, Sherwood LJ, Osborn LE, Cummins LB, Hayhurst A (2006) Facile generation of heat-stable antiviral and antitoxin single domain antibodies from a semisynthetic llama library. Anal Chem 78:8245&#x2013;8255 <pub-id pub-id-type="pmid">17165813</pub-id></citation>
      </ref>
      <ref id="CR28">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Greenberg</surname>
              <given-names>AS</given-names>
            </name>
            <name>
              <surname>Avila</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Hughes</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Hughes</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>McKinney</surname>
              <given-names>EC</given-names>
            </name>
            <name>
              <surname>Flajnik</surname>
              <given-names>MF</given-names>
            </name>
          </person-group>
          <article-title>A new antigen receptor gene family that undergoes rearrangement and extensive somatic diversification in sharks</article-title>
          <source>Nature</source>
          <year>1995</year>
          <volume>374</volume>
          <fpage>168</fpage>
          <lpage>173</lpage>
          <pub-id pub-id-type="doi">10.1038/374168a0</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Greenberg AS, Avila D, Hughes M, Hughes A, McKinney EC, Flajnik MF (1995) A new antigen receptor gene family that undergoes rearrangement and extensive somatic diversification in sharks. Nature 374:168&#x2013;173 <pub-id pub-id-type="pmid">7877689</pub-id></citation>
      </ref>
      <ref id="CR29">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gueorguieva</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Walsh</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Mukerji</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Tanha</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Pandey</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Identification of single-domain, Bax-specific intrabodies that confer resistance to mammalian cells against oxidative-stress-induced apoptosis</article-title>
          <source>FASEB J</source>
          <year>2006</year>
          <volume>20</volume>
          <fpage>2636</fpage>
          <lpage>2638</lpage>
          <pub-id pub-id-type="doi">10.1096/fj.06-6306fje</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Gueorguieva D, Li S, Walsh N, Mukerji A, Tanha J, Pandey S (2006) Identification of single-domain, Bax-specific intrabodies that confer resistance to mammalian cells against oxidative-stress-induced apoptosis. FASEB J 20:2636&#x2013;2638 <pub-id pub-id-type="pmid">17060401</pub-id></citation>
      </ref>
      <ref id="CR30">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hamers-Casterman</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Atarhouch</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Muyldermans</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Robinson</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Hamers</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Songa</surname>
              <given-names>EB</given-names>
            </name>
            <name>
              <surname>Bendahman</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Hamers</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Naturally occurring antibodies devoid of light chains</article-title>
          <source>Nature</source>
          <year>1993</year>
          <volume>363</volume>
          <fpage>446</fpage>
          <lpage>448</lpage>
          <pub-id pub-id-type="doi">10.1038/363446a0</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Hamers-Casterman C, Atarhouch T, Muyldermans S, Robinson G, Hamers C, Songa EB, Bendahman N, Hamers R (1993) Naturally occurring antibodies devoid of light chains. Nature 363:446&#x2013;448 <pub-id pub-id-type="pmid">8502296</pub-id></citation>
      </ref>
      <ref id="CR31">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hamilton</surname>
              <given-names>SR</given-names>
            </name>
            <name>
              <surname>Davidson</surname>
              <given-names>RC</given-names>
            </name>
            <name>
              <surname>Sethuraman</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Nett</surname>
              <given-names>JH</given-names>
            </name>
            <name>
              <surname>Jiang</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Rios</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Bobrowicz</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Stadheim</surname>
              <given-names>TA</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Choi</surname>
              <given-names>BK</given-names>
            </name>
            <name>
              <surname>Hopkins</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Wischnewski</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Roser</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Mitchell</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Strawbridge</surname>
              <given-names>RR</given-names>
            </name>
            <name>
              <surname>Hoopes</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Wildt</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Gerngross</surname>
              <given-names>TU</given-names>
            </name>
          </person-group>
          <article-title>Humanization of yeast to produce complex terminally sialylated glycoproteins</article-title>
          <source>Science</source>
          <year>2006</year>
          <volume>313</volume>
          <fpage>1441</fpage>
          <lpage>1443</lpage>
          <pub-id pub-id-type="doi">10.1126/science.1130256</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Hamilton SR, Davidson RC, Sethuraman N, Nett JH, Jiang Y, Rios S, Bobrowicz P, Stadheim TA, Li H, Choi BK, Hopkins D, Wischnewski H, Roser J, Mitchell T, Strawbridge RR, Hoopes J, Wildt S, Gerngross TU (2006) Humanization of yeast to produce complex terminally sialylated glycoproteins. Science 313:1441&#x2013;1443 <pub-id pub-id-type="pmid">16960007</pub-id></citation>
      </ref>
      <ref id="CR32">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Harmsen</surname>
              <given-names>MM</given-names>
            </name>
            <name>
              <surname>Ruuls</surname>
              <given-names>RC</given-names>
            </name>
            <name>
              <surname>Nijman</surname>
              <given-names>IJ</given-names>
            </name>
            <name>
              <surname>Niewold</surname>
              <given-names>TA</given-names>
            </name>
            <name>
              <surname>Frenken</surname>
              <given-names>LGJ</given-names>
            </name>
            <name>
              <surname>Geus</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>Llama heavy-chain V regions consist of at least four distinct subfamilies revealing novel sequence features</article-title>
          <source>Mol Immunol</source>
          <year>2000</year>
          <volume>37</volume>
          <fpage>579</fpage>
          <lpage>590</lpage>
          <pub-id pub-id-type="doi">10.1016/S0161-5890(00)00081-X</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Harmsen MM, Ruuls RC, Nijman IJ, Niewold TA, Frenken LGJ, de Geus B (2000) Llama heavy-chain V regions consist of at least four distinct subfamilies revealing novel sequence features. Mol Immunol 37:579&#x2013;590 <pub-id pub-id-type="pmid">11163394</pub-id></citation>
      </ref>
      <ref id="CR33">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Harmsen</surname>
              <given-names>MM</given-names>
            </name>
            <name>
              <surname>Solt</surname>
              <given-names>CB</given-names>
            </name>
            <name>
              <surname>Fijten</surname>
              <given-names>HPD</given-names>
            </name>
            <name>
              <surname>Setten</surname>
              <given-names>MC</given-names>
            </name>
          </person-group>
          <article-title>Prolonged in vivo residence times of llama single-domain antibody fragments in pigs by binding to porcine immunoglobulins</article-title>
          <source>Vaccine</source>
          <year>2005</year>
          <volume>23</volume>
          <fpage>4926</fpage>
          <lpage>4934</lpage>
          <pub-id pub-id-type="doi">10.1016/j.vaccine.2005.05.017</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Harmsen MM, Van Solt CB, Fijten HPD, Van Setten MC (2005a) Prolonged in vivo residence times of llama single-domain antibody fragments in pigs by binding to porcine immunoglobulins. Vaccine 23:4926&#x2013;4934 <pub-id pub-id-type="pmid">15992972</pub-id></citation>
      </ref>
      <ref id="CR34">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Harmsen</surname>
              <given-names>MM</given-names>
            </name>
            <name>
              <surname>Solt</surname>
              <given-names>CB</given-names>
            </name>
            <name>
              <surname>Hoogendoorn</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Zijderveld</surname>
              <given-names>FG</given-names>
            </name>
            <name>
              <surname>Niewold</surname>
              <given-names>TA</given-names>
            </name>
            <name>
              <surname>Meulen</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Escherichia coli F4 fimbriae specific llama single-domain antibody fragments effectively inhibit bacterial adhesion in vitro but poorly protect against diarrhoea</article-title>
          <source>Vet Microbiol</source>
          <year>2005</year>
          <volume>111</volume>
          <fpage>89</fpage>
          <lpage>98</lpage>
          <pub-id pub-id-type="doi">10.1016/j.vetmic.2005.09.005</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Harmsen MM, van Solt CB, Hoogendoorn A, van Zijderveld FG, Niewold TA, van der Meulen J (2005b) Escherichia coli F4 fimbriae specific llama single-domain antibody fragments effectively inhibit bacterial adhesion in vitro but poorly protect against diarrhoea. Vet Microbiol 111:89&#x2013;98 <pub-id pub-id-type="pmid">16221532</pub-id></citation>
      </ref>
      <ref id="CR35">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Harmsen</surname>
              <given-names>MM</given-names>
            </name>
            <name>
              <surname>Solt</surname>
              <given-names>CB</given-names>
            </name>
            <name>
              <surname>Zijderveld-van Bemmel</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Niewold</surname>
              <given-names>TA</given-names>
            </name>
            <name>
              <surname>Zijderveld</surname>
              <given-names>FG</given-names>
            </name>
          </person-group>
          <article-title>Selection and optimization of proteolytically stable llama single-domain antibody fragments for oral immunotherapy</article-title>
          <source>Appl Microbiol Biotechnol</source>
          <year>2006</year>
          <volume>72</volume>
          <fpage>544</fpage>
          <lpage>551</lpage>
          <pub-id pub-id-type="doi">10.1007/s00253-005-0300-7</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Harmsen MM, van Solt CB, van Zijderveld-van Bemmel AM, Niewold TA, van Zijderveld FG (2006) Selection and optimization of proteolytically stable llama single-domain antibody fragments for oral immunotherapy. Appl Microbiol Biotechnol 72:544&#x2013;551 <pub-id pub-id-type="pmid">16450109</pub-id></citation>
      </ref>
      <ref id="CR36">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Harmsen</surname>
              <given-names>MM</given-names>
            </name>
            <name>
              <surname>Solt</surname>
              <given-names>CB</given-names>
            </name>
            <name>
              <surname>Fijten</surname>
              <given-names>HPD</given-names>
            </name>
            <name>
              <surname>Keulen</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Rosalia</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Weerdmeester</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Cornelissen</surname>
              <given-names>AHM</given-names>
            </name>
            <name>
              <surname>Bruin</surname>
              <given-names>MGM</given-names>
            </name>
            <name>
              <surname>Ebl&#xE9;</surname>
              <given-names>PL</given-names>
            </name>
            <name>
              <surname>Dekker</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Passive immunization of guinea-pigs with llama single-domain antibody fragments against foot-and-mouth disease</article-title>
          <source>Vet Microbiol</source>
          <year>2007</year>
          <volume>120</volume>
          <fpage>193</fpage>
          <lpage>206</lpage>
          <pub-id pub-id-type="doi">10.1016/j.vetmic.2006.10.029</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Harmsen MM, Van Solt CB, Fijten HPD, Van Keulen L, Rosalia RA, Weerdmeester K, Cornelissen AHM, De Bruin MGM, Ebl&#xE9; PL, Dekker A (2007) Passive immunization of guinea-pigs with llama single-domain antibody fragments against foot-and-mouth disease. Vet Microbiol 120:193&#x2013;206 <pub-id pub-id-type="pmid">17127019</pub-id></citation>
      </ref>
      <ref id="CR37">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Harrison</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Hasson</surname>
              <given-names>SS</given-names>
            </name>
            <name>
              <surname>Harmsen</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Laing</surname>
              <given-names>GD</given-names>
            </name>
            <name>
              <surname>Conrath</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Theakston</surname>
              <given-names>RD</given-names>
            </name>
          </person-group>
          <article-title>Neutralisation of venom-induced haemorrhage by IgG from camels and llamas immunised with viper venom and also by endogenous, non-IgG components in camelid sera</article-title>
          <source>Toxicon</source>
          <year>2006</year>
          <volume>47</volume>
          <fpage>364</fpage>
          <lpage>368</lpage>
          <pub-id pub-id-type="doi">10.1016/j.toxicon.2005.10.017</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Harrison RA, Hasson SS, Harmsen M, Laing GD, Conrath K, Theakston RD (2006) Neutralisation of venom-induced haemorrhage by IgG from camels and llamas immunised with viper venom and also by endogenous, non-IgG components in camelid sera. Toxicon 47:364&#x2013;368 <pub-id pub-id-type="pmid">16359717</pub-id></citation>
      </ref>
      <ref id="CR38">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hermeling</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Crommelin</surname>
              <given-names>DJ</given-names>
            </name>
            <name>
              <surname>Schellekens</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Jiskoot</surname>
              <given-names>W</given-names>
            </name>
          </person-group>
          <article-title>Structure&#x2013;immunogenicity relationships of therapeutic proteins</article-title>
          <source>Pharm Res</source>
          <year>2004</year>
          <volume>21</volume>
          <fpage>897</fpage>
          <lpage>903</lpage>
          <pub-id pub-id-type="doi">10.1023/B:PHAM.0000029275.41323.a6</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Hermeling S, Crommelin DJ, Schellekens H, Jiskoot W (2004) Structure&#x2013;immunogenicity relationships of therapeutic proteins. Pharm Res 21:897&#x2013;903 <pub-id pub-id-type="pmid">15212151</pub-id></citation>
      </ref>
      <ref id="CR39">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Holliger</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Hudson</surname>
              <given-names>PJ</given-names>
            </name>
          </person-group>
          <article-title>Engineered antibody fragments and the rise of single domains</article-title>
          <source>Nat Biotechnol</source>
          <year>2005</year>
          <volume>23</volume>
          <fpage>1126</fpage>
          <lpage>1136</lpage>
          <pub-id pub-id-type="doi">10.1038/nbt1142</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Holliger P, Hudson PJ (2005) Engineered antibody fragments and the rise of single domains. Nat Biotechnol 23:1126&#x2013;1136 <pub-id pub-id-type="pmid">16151406</pub-id></citation>
      </ref>
      <ref id="CR40">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Holliger</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Wing</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Pound</surname>
              <given-names>JD</given-names>
            </name>
            <name>
              <surname>Bohlen</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Winter</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Retargeting serum immunoglobulin with bispecific diabodies</article-title>
          <source>Nat Biotechnol</source>
          <year>1997</year>
          <volume>15</volume>
          <fpage>632</fpage>
          <lpage>636</lpage>
          <pub-id pub-id-type="doi">10.1038/nbt0797-632</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Holliger P, Wing M, Pound JD, Bohlen H, Winter G (1997) Retargeting serum immunoglobulin with bispecific diabodies. Nat Biotechnol 15:632&#x2013;636 <pub-id pub-id-type="pmid">9219264</pub-id></citation>
      </ref>
      <ref id="CR41">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Janssens</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Dekker</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Hendriks</surname>
              <given-names>RW</given-names>
            </name>
            <name>
              <surname>Panayotou</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Remoortere</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>San</surname>
              <given-names>JK</given-names>
            </name>
            <name>
              <surname>Grosveld</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Drabek</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>Generation of heavy-chain-only antibodies in mice</article-title>
          <source>Proc Natl Acad Sci USA</source>
          <year>2006</year>
          <volume>103</volume>
          <fpage>15130</fpage>
          <lpage>15135</lpage>
          <pub-id pub-id-type="doi">10.1073/pnas.0601108103</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Janssens R, Dekker S, Hendriks RW, Panayotou G, van Remoortere A, San JK, Grosveld F, Drabek D (2006) Generation of heavy-chain-only antibodies in mice. Proc Natl Acad Sci USA 103:15130&#x2013;15135 <pub-id pub-id-type="pmid">17015837</pub-id></citation>
      </ref>
      <ref id="CR42">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jespers</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Schon</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Famm</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Winter</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Aggregation-resistant domain antibodies selected on phage by heat denaturation</article-title>
          <source>Nat Biotechnol</source>
          <year>2004</year>
          <volume>22</volume>
          <fpage>1161</fpage>
          <lpage>1165</lpage>
          <pub-id pub-id-type="doi">10.1038/nbt1000</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Jespers L, Schon O, Famm K, Winter G (2004) Aggregation-resistant domain antibodies selected on phage by heat denaturation. Nat Biotechnol 22:1161&#x2013;1165 <pub-id pub-id-type="pmid">15300256</pub-id></citation>
      </ref>
      <ref id="CR43">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Joosten</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Roelofs</surname>
              <given-names>MS</given-names>
            </name>
            <name>
              <surname>Dries</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Goosen</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Verrips</surname>
              <given-names>CT</given-names>
            </name>
            <name>
              <surname>Hondel</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Lokman</surname>
              <given-names>BC</given-names>
            </name>
          </person-group>
          <article-title>Production of bifunctional proteins by <italic>Aspergillus awamori</italic>: llama variable heavy chain antibody fragment (V(HH)) R9 coupled to <italic>Arthromyces ramosus</italic> peroxidase (ARP)</article-title>
          <source>J Biotechnol</source>
          <year>2005</year>
          <volume>120</volume>
          <fpage>347</fpage>
          <lpage>359</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jbiotec.2005.06.034</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Joosten V, Roelofs MS, van den Dries N, Goosen T, Verrips CT, van den Hondel CA, Lokman BC (2005) Production of bifunctional proteins by Aspergillus awamori: llama variable heavy chain antibody fragment (V(HH)) R9 coupled to Arthromyces ramosus peroxidase (ARP). J Biotechnol 120:347&#x2013;359 <pub-id pub-id-type="pmid">16169108</pub-id></citation>
      </ref>
      <ref id="CR44">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kruger</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Hultberg</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Marcotte</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Hermans</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Bezemer</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Frenken</surname>
              <given-names>LG</given-names>
            </name>
            <name>
              <surname>Hammarstrom</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
          <article-title>Therapeutic effect of llama derived VHH fragments against <italic>Streptococcus mutans</italic> on the development of dental caries</article-title>
          <source>Appl Microbiol Biotechnol</source>
          <year>2006</year>
          <volume>72</volume>
          <fpage>732</fpage>
          <lpage>737</lpage>
          <pub-id pub-id-type="doi">10.1007/s00253-006-0347-0</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Kruger C, Hultberg A, Marcotte H, Hermans P, Bezemer S, Frenken LG, Hammarstrom L (2006) Therapeutic effect of llama derived VHH fragments against Streptococcus mutans on the development of dental caries. Appl Microbiol Biotechnol 72:732&#x2013;737 <pub-id pub-id-type="pmid">16636830</pub-id></citation>
      </ref>
      <ref id="CR45">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lange</surname>
              <given-names>IG</given-names>
            </name>
            <name>
              <surname>Daxenberger</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Meyer</surname>
              <given-names>HH</given-names>
            </name>
          </person-group>
          <article-title>Studies on the antibody response of <italic>Lama glama</italic>&#x2014;evaluation of the binding capacity of different IgG subtypes in ELISAs for clenbuterol and BSA</article-title>
          <source>Vet Immunol Immunopathol</source>
          <year>2001</year>
          <volume>83</volume>
          <fpage>1</fpage>
          <lpage>9</lpage>
          <pub-id pub-id-type="doi">10.1016/S0165-2427(01)00376-2</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Lange IG, Daxenberger A, Meyer HH (2001) Studies on the antibody response of Lama glama&#x2014;evaluation of the binding capacity of different IgG subtypes in ELISAs for clenbuterol and BSA. Vet Immunol Immunopathol 83:1&#x2013;9 <pub-id pub-id-type="pmid">11604157</pub-id></citation>
      </ref>
      <ref id="CR46">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lauwereys</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Arbabi Ghahroudi</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Desmyter</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Kinne</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Holzer</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Genst</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Wyns</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Muyldermans</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Potent enzyme inhibitors derived from dromedary heavy-chain antibodies</article-title>
          <source>Embo J</source>
          <year>1998</year>
          <volume>17</volume>
          <fpage>3512</fpage>
          <lpage>3520</lpage>
          <pub-id pub-id-type="doi">10.1093/emboj/17.13.3512</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Lauwereys M, Arbabi Ghahroudi M, Desmyter A, Kinne J, Holzer W, De Genst E, Wyns L, Muyldermans S (1998) Potent enzyme inhibitors derived from dromedary heavy-chain antibodies. Embo J 17:3512&#x2013;3520 <pub-id pub-id-type="pmid">9649422</pub-id></citation>
      </ref>
      <ref id="CR47">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lesk</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Chothia</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Elbow motion in the immunoglobulins involves a molecular ball-and-socket joint</article-title>
          <source>Nature</source>
          <year>1988</year>
          <volume>335</volume>
          <fpage>188</fpage>
          <lpage>190</lpage>
          <pub-id pub-id-type="doi">10.1038/335188a0</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Lesk AM, Chothia C (1988) Elbow motion in the immunoglobulins involves a molecular ball-and-socket joint. Nature 335:188&#x2013;190 <pub-id pub-id-type="pmid">3412476</pub-id></citation>
      </ref>
      <ref id="CR48">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Muruganandam</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Tanha</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Narang</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Stanimirovic</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>Selection of phage-displayed llama single-domain antibodies that transmigrate across human blood-brain barrier endothelium</article-title>
          <source>Faseb J</source>
          <year>2002</year>
          <volume>16</volume>
          <fpage>240</fpage>
          <lpage>242</lpage>
        </citation>
        <citation citation-type="display-unstructured">Muruganandam A, Tanha J, Narang S, Stanimirovic D (2002) Selection of phage-displayed llama single-domain antibodies that transmigrate across human blood-brain barrier endothelium. Faseb J 16:240&#x2013;242 <pub-id pub-id-type="pmid">11772942</pub-id></citation>
      </ref>
      <ref id="CR49">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Muyldermans</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Single domain camel antibodies: current status</article-title>
          <source>J Biotechnol</source>
          <year>2001</year>
          <volume>74</volume>
          <fpage>277</fpage>
          <lpage>302</lpage>
        </citation>
        <citation citation-type="display-unstructured">Muyldermans S (2001) Single domain camel antibodies: current status. J Biotechnol 74:277&#x2013;302 <pub-id pub-id-type="pmid">11526908</pub-id></citation>
      </ref>
      <ref id="CR50">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Muyldermans</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Atarhouch</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Saldanha</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Barbosa</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Hamers</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Sequence and structure of VH domain from naturally occurring camel heavy chain immunoglobulins lacking light chains</article-title>
          <source>Protein Eng</source>
          <year>1994</year>
          <volume>7</volume>
          <fpage>1129</fpage>
          <lpage>35</lpage>
          <pub-id pub-id-type="doi">10.1093/protein/7.9.1129</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Muyldermans S, Atarhouch T, Saldanha J, Barbosa JA, Hamers R (1994) Sequence and structure of VH domain from naturally occurring camel heavy chain immunoglobulins lacking light chains. Protein Eng 7:1129&#x2013;35 <pub-id pub-id-type="pmid">7831284</pub-id></citation>
      </ref>
      <ref id="CR51">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Muyldermans</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Cambillau</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Wyns</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
          <article-title>Recognition of antigens by single-domain antibody fragments: the superfluous luxury of paired domains</article-title>
          <source>Trends Biochem Sci</source>
          <year>2001</year>
          <volume>26</volume>
          <fpage>230</fpage>
          <lpage>235</lpage>
          <pub-id pub-id-type="doi">10.1016/S0968-0004(01)01790-X</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Muyldermans S, Cambillau C, Wyns L (2001) Recognition of antigens by single-domain antibody fragments: the superfluous luxury of paired domains. Trends Biochem Sci 26:230&#x2013;235 <pub-id pub-id-type="pmid">11295555</pub-id></citation>
      </ref>
      <ref id="CR52">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nguyen</surname>
              <given-names>VK</given-names>
            </name>
            <name>
              <surname>Hamers</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Wyns</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Muyldermans</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Camel heavy-chain antibodies: diverse germline V(H)H and specific mechanisms enlarge the antigen-binding repertoire</article-title>
          <source>Embo J</source>
          <year>2000</year>
          <volume>19</volume>
          <fpage>921</fpage>
          <lpage>930</lpage>
          <pub-id pub-id-type="doi">10.1093/emboj/19.5.921</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Nguyen VK, Hamers R, Wyns L, Muyldermans S (2000) Camel heavy-chain antibodies: diverse germline V(H)H and specific mechanisms enlarge the antigen-binding repertoire. Embo J 19:921&#x2013;930 <pub-id pub-id-type="pmid">10698934</pub-id></citation>
      </ref>
      <ref id="CR53">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nguyen</surname>
              <given-names>VK</given-names>
            </name>
            <name>
              <surname>Zou</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Lauwereys</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Brys</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Bruggemann</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Muyldermans</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Heavy-chain only antibodies derived from dromedary are secreted and displayed by mouse B cells</article-title>
          <source>Immunology</source>
          <year>2003</year>
          <volume>109</volume>
          <fpage>93</fpage>
          <lpage>101</lpage>
          <pub-id pub-id-type="doi">10.1046/j.1365-2567.2003.01633.x</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Nguyen VK, Zou X, Lauwereys M, Brys L, Bruggemann M, Muyldermans S (2003) Heavy-chain only antibodies derived from dromedary are secreted and displayed by mouse B cells. Immunology 109:93&#x2013;101 <pub-id pub-id-type="pmid">12709022</pub-id></citation>
      </ref>
      <ref id="CR54">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nieba</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Honegger</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Krebber</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Pluckthun</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Disrupting the hydrophobic patches at the antibody variable/constant domain interface: improved in vivo folding and physical characterization of an engineered scFv fragment</article-title>
          <source>Protein Eng</source>
          <year>1997</year>
          <volume>10</volume>
          <fpage>435</fpage>
          <lpage>444</lpage>
          <pub-id pub-id-type="doi">10.1093/protein/10.4.435</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Nieba L, Honegger A, Krebber C, Pluckthun A (1997) Disrupting the hydrophobic patches at the antibody variable/constant domain interface: improved in vivo folding and physical characterization of an engineered scFv fragment. Protein Eng 10:435&#x2013;444 <pub-id pub-id-type="pmid">9194169</pub-id></citation>
      </ref>
      <ref id="CR55">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nowakowski</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Powers</surname>
              <given-names>DB</given-names>
            </name>
            <name>
              <surname>Amersdorfer</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Smith</surname>
              <given-names>TJ</given-names>
            </name>
            <name>
              <surname>Montgomery</surname>
              <given-names>VA</given-names>
            </name>
            <name>
              <surname>Sheridan</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Blake</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Smith</surname>
              <given-names>LA</given-names>
            </name>
            <name>
              <surname>Marks</surname>
              <given-names>JD</given-names>
            </name>
          </person-group>
          <article-title>Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody</article-title>
          <source>Proc Natl Acad Sci USA</source>
          <year>2002</year>
          <volume>99</volume>
          <fpage>11346</fpage>
          <lpage>11350</lpage>
          <pub-id pub-id-type="doi">10.1073/pnas.172229899</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Nowakowski A, Wang C, Powers DB, Amersdorfer P, Smith TJ, Montgomery VA, Sheridan R, Blake R, Smith LA, Marks JD (2002) Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody. Proc Natl Acad Sci USA 99:11346&#x2013;11350 <pub-id pub-id-type="pmid">12177434</pub-id></citation>
      </ref>
      <ref id="CR56">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Olichon</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Schweizer</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Muyldermans</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Marco</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Heating as a rapid purification method for recovering correctly-folded thermotolerant VH and VHH domains</article-title>
          <source>BMC Biotechnol</source>
          <year>2007</year>
          <volume>7</volume>
          <fpage>7</fpage>
          <pub-id pub-id-type="doi">10.1186/1472-6750-7-7</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Olichon A, Schweizer D, Muyldermans S, de Marco A (2007) Heating as a rapid purification method for recovering correctly-folded thermotolerant VH and VHH domains. BMC Biotechnol 7:7 <pub-id pub-id-type="pmid">17257422</pub-id></citation>
      </ref>
      <ref id="CR57">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pant</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Hultberg</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Zhao</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Svensson</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Pan-Hammarstrom</surname>
              <given-names>Q</given-names>
            </name>
            <name>
              <surname>Johansen</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Pouwels</surname>
              <given-names>PH</given-names>
            </name>
            <name>
              <surname>Ruggeri</surname>
              <given-names>FM</given-names>
            </name>
            <name>
              <surname>Hermans</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Frenken</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Boren</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Marcotte</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Hammarstrom</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
          <article-title>Lactobacilli expressing variable domain of llama heavy-chain antibody fragments (lactobodies) confer protection against rotavirus-induced diarrhea</article-title>
          <source>J Infect Dis</source>
          <year>2006</year>
          <volume>194</volume>
          <fpage>1580</fpage>
          <lpage>1588</lpage>
          <pub-id pub-id-type="doi">10.1086/508747</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Pant N, Hultberg A, Zhao Y, Svensson L, Pan-Hammarstrom Q, Johansen K, Pouwels PH, Ruggeri FM, Hermans P, Frenken L, Boren T, Marcotte H, Hammarstrom L (2006) Lactobacilli expressing variable domain of llama heavy-chain antibody fragments (lactobodies) confer protection against rotavirus-induced diarrhea. J Infect Dis 194:1580&#x2013;1588 <pub-id pub-id-type="pmid">17083044</pub-id></citation>
      </ref>
      <ref id="CR58">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Perez</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Renisio</surname>
              <given-names>JG</given-names>
            </name>
            <name>
              <surname>Prompers</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Platerink</surname>
              <given-names>CJ</given-names>
            </name>
            <name>
              <surname>Cambillau</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Darbon</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Frenken</surname>
              <given-names>LG</given-names>
            </name>
          </person-group>
          <article-title>Thermal unfolding of a llama antibody fragment: a two-state reversible process</article-title>
          <source>Biochemistry</source>
          <year>2001</year>
          <volume>40</volume>
          <fpage>74</fpage>
          <lpage>83</lpage>
          <pub-id pub-id-type="doi">10.1021/bi0009082</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Perez JM, Renisio JG, Prompers JJ, van Platerink CJ, Cambillau C, Darbon H, Frenken LG (2001) Thermal unfolding of a llama antibody fragment: a two-state reversible process. Biochemistry 40:74&#x2013;83 <pub-id pub-id-type="pmid">11141058</pub-id></citation>
      </ref>
      <ref id="CR59">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pleschberger</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Saerens</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Weigert</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Sleytr</surname>
              <given-names>UB</given-names>
            </name>
            <name>
              <surname>Muyldermans</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Sara</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Egelseer</surname>
              <given-names>EM</given-names>
            </name>
          </person-group>
          <article-title>An S-layer heavy chain camel antibody fusion protein for generation of a nanopatterned sensing layer to detect the prostate-specific antigen by surface plasmon resonance technology</article-title>
          <source>Bioconjug Chem</source>
          <year>2004</year>
          <volume>15</volume>
          <fpage>664</fpage>
          <lpage>671</lpage>
          <pub-id pub-id-type="doi">10.1021/bc049964w</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Pleschberger M, Saerens D, Weigert S, Sleytr UB, Muyldermans S, Sara M, Egelseer EM (2004) An S-layer heavy chain camel antibody fusion protein for generation of a nanopatterned sensing layer to detect the prostate-specific antigen by surface plasmon resonance technology. Bioconjug Chem 15:664&#x2013;671 <pub-id pub-id-type="pmid">15149195</pub-id></citation>
      </ref>
      <ref id="CR60">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Presta</surname>
              <given-names>LG</given-names>
            </name>
          </person-group>
          <article-title>Engineering of therapeutic antibodies to minimize immunogenicity and optimize function</article-title>
          <source>Adv Drug Deliv Rev</source>
          <year>2006</year>
          <volume>58</volume>
          <fpage>640</fpage>
          <lpage>656</lpage>
          <pub-id pub-id-type="doi">10.1016/j.addr.2006.01.026</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Presta LG (2006) Engineering of therapeutic antibodies to minimize immunogenicity and optimize function. Adv Drug Deliv Rev 58:640&#x2013;656 <pub-id pub-id-type="pmid">16904789</pub-id></citation>
      </ref>
      <ref id="CR61">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rahbarizadeh</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Rasaee</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Forouzandeh-Moghadam</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Allameh</surname>
              <given-names>AA</given-names>
            </name>
          </person-group>
          <article-title>High expression and purification of the recombinant camelid anti-MUC1 single domain antibodies in Escherichia coli</article-title>
          <source>Protein Expr Purif</source>
          <year>2005</year>
          <volume>44</volume>
          <fpage>32</fpage>
          <lpage>38</lpage>
          <pub-id pub-id-type="doi">10.1016/j.pep.2005.04.008</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Rahbarizadeh F, Rasaee MJ, Forouzandeh-Moghadam M, Allameh AA (2005) High expression and purification of the recombinant camelid anti-MUC1 single domain antibodies in Escherichia coli. Protein Expr Purif 44:32&#x2013;38 <pub-id pub-id-type="pmid">15922625</pub-id></citation>
      </ref>
      <ref id="CR62">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rahbarizadeh</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Rasaee</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Forouzandeh</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Allameh</surname>
              <given-names>AA</given-names>
            </name>
          </person-group>
          <article-title>Over expression of anti-MUC1 single-domain antibody fragments in the yeast <italic>Pichia pastoris</italic></article-title>
          <source>Mol Immunol</source>
          <year>2006</year>
          <volume>43</volume>
          <fpage>426</fpage>
          <lpage>435</lpage>
          <pub-id pub-id-type="doi">10.1016/j.molimm.2005.03.003</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Rahbarizadeh F, Rasaee MJ, Forouzandeh M, Allameh AA (2006) Over expression of anti-MUC1 single-domain antibody fragments in the yeast Pichia pastoris. Mol Immunol 43:426&#x2013;435 <pub-id pub-id-type="pmid">16337485</pub-id></citation>
      </ref>
      <ref id="CR63">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Reichert</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Valge-Archer</surname>
              <given-names>VE</given-names>
            </name>
          </person-group>
          <article-title>Development trends for monoclonal antibody cancer therapeutics</article-title>
          <source>Nat Rev Drug Discov</source>
          <year>2007</year>
          <volume>6</volume>
          <fpage>349</fpage>
          <lpage>356</lpage>
          <pub-id pub-id-type="doi">10.1038/nrd2241</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Reichert JM, Valge-Archer VE (2007) Development trends for monoclonal antibody cancer therapeutics. Nat Rev Drug Discov 6:349&#x2013;356 <pub-id pub-id-type="pmid">17431406</pub-id></citation>
      </ref>
      <ref id="CR64">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Revets</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Baetselier</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Muyldermans</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Nanobodies as novel agents for cancer therapy</article-title>
          <source>Expert Opin Biol Ther</source>
          <year>2005</year>
          <volume>5</volume>
          <fpage>111</fpage>
          <lpage>124</lpage>
          <pub-id pub-id-type="doi">10.1517/14712598.5.1.111</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Revets H, De Baetselier P, Muyldermans S (2005) Nanobodies as novel agents for cancer therapy. Expert Opin Biol Ther 5:111&#x2013;124 <pub-id pub-id-type="pmid">15709914</pub-id></citation>
      </ref>
      <ref id="CR65">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Roovers</surname>
              <given-names>RC</given-names>
            </name>
            <name>
              <surname>Laeremans</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Huang</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Taeye</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Verkleij</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Revets</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Haard</surname>
              <given-names>HJ</given-names>
            </name>
            <name>
              <surname>Bergen en Henegouwen</surname>
              <given-names>PM</given-names>
            </name>
          </person-group>
          <article-title>Efficient inhibition of EGFR signaling and of tumour growth by antagonistic anti-EFGR Nanobodies</article-title>
          <source>Cancer Immunol Immunother</source>
          <year>2007</year>
          <volume>56</volume>
          <fpage>303</fpage>
          <lpage>317</lpage>
          <pub-id pub-id-type="doi">10.1007/s00262-006-0180-4</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Roovers RC, Laeremans T, Huang L, De Taeye S, Verkleij AJ, Revets H, De Haard HJ, Van Bergen en Henegouwen PM (2007) Efficient inhibition of EGFR signaling and of tumour growth by antagonistic anti-EFGR Nanobodies. Cancer Immunol Immunother 56:303&#x2013;317 <pub-id pub-id-type="pmid">16738850</pub-id></citation>
      </ref>
      <ref id="CR66">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rothbauer</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Zolghadr</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Tillib</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Nowak</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Schermelleh</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Gahl</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Backmann</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Conrath</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Muyldermans</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Cardoso</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Leonhardt</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Targeting and tracing antigens in live cells with fluorescent nanobodies</article-title>
          <source>Nat Methods</source>
          <year>2006</year>
          <volume>3</volume>
          <fpage>887</fpage>
          <lpage>889</lpage>
          <pub-id pub-id-type="doi">10.1038/nmeth953</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Rothbauer U, Zolghadr K, Tillib S, Nowak D, Schermelleh L, Gahl A, Backmann N, Conrath K, Muyldermans S, Cardoso MC, Leonhardt H (2006) Targeting and tracing antigens in live cells with fluorescent nanobodies. Nat Methods 3:887&#x2013;889 <pub-id pub-id-type="pmid">17060912</pub-id></citation>
      </ref>
      <ref id="CR67">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Saerens</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Kinne</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Bosmans</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Wernery</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Muyldermans</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Conrath</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Single domain antibodies derived from dromedary lymph node and peripheral blood lymphocytes sensing conformational variants of prostate-specific antigen</article-title>
          <source>J Biol Chem</source>
          <year>2004</year>
          <volume>279</volume>
          <fpage>51965</fpage>
          <lpage>51972</lpage>
          <pub-id pub-id-type="doi">10.1074/jbc.M409292200</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Saerens D, Kinne J, Bosmans E, Wernery U, Muyldermans S, Conrath K (2004) Single domain antibodies derived from dromedary lymph node and peripheral blood lymphocytes sensing conformational variants of prostate-specific antigen. J Biol Chem 279:51965&#x2013;51972 <pub-id pub-id-type="pmid">15459193</pub-id></citation>
      </ref>
      <ref id="CR68">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sagt</surname>
              <given-names>CM</given-names>
            </name>
            <name>
              <surname>Kleizen</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Verwaal</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Jong</surname>
              <given-names>MD</given-names>
            </name>
            <name>
              <surname>Muller</surname>
              <given-names>WH</given-names>
            </name>
            <name>
              <surname>Smits</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Visser</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Boonstra</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Verkleij</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Verrips</surname>
              <given-names>CT</given-names>
            </name>
          </person-group>
          <article-title>Introduction of an N-glycosylation site increases secretion of heterologous proteins in yeasts</article-title>
          <source>Appl Environ Microbiol</source>
          <year>2000</year>
          <volume>66</volume>
          <fpage>4940</fpage>
          <lpage>4944</lpage>
          <pub-id pub-id-type="doi">10.1128/AEM.66.11.4940-4944.2000</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Sagt CM, Kleizen B, Verwaal R, de Jong MD, Muller WH, Smits A, Visser C, Boonstra J, Verkleij AJ, Verrips CT (2000) Introduction of an N-glycosylation site increases secretion of heterologous proteins in yeasts. Appl Environ Microbiol 66:4940&#x2013;4944 <pub-id pub-id-type="pmid">11055947</pub-id></citation>
      </ref>
      <ref id="CR69">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sethuraman</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Stadheim</surname>
              <given-names>TA</given-names>
            </name>
          </person-group>
          <article-title>Challenges in therapeutic glycoprotein production</article-title>
          <source>Curr Opin Biotechnol</source>
          <year>2006</year>
          <volume>17</volume>
          <fpage>341</fpage>
          <lpage>346</lpage>
          <pub-id pub-id-type="doi">10.1016/j.copbio.2006.06.010</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Sethuraman N, Stadheim TA (2006) Challenges in therapeutic glycoprotein production. Curr Opin Biotechnol 17:341&#x2013;346 <pub-id pub-id-type="pmid">16828275</pub-id></citation>
      </ref>
      <ref id="CR70">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Simmons</surname>
              <given-names>DP</given-names>
            </name>
            <name>
              <surname>Abregu</surname>
              <given-names>FA</given-names>
            </name>
            <name>
              <surname>Krishnan</surname>
              <given-names>UV</given-names>
            </name>
            <name>
              <surname>Proll</surname>
              <given-names>DF</given-names>
            </name>
            <name>
              <surname>Streltsov</surname>
              <given-names>VA</given-names>
            </name>
            <name>
              <surname>Doughty</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Hattarki</surname>
              <given-names>MK</given-names>
            </name>
            <name>
              <surname>Nuttall</surname>
              <given-names>SD</given-names>
            </name>
          </person-group>
          <article-title>Dimerisation strategies for shark IgNAR single domain antibody fragments</article-title>
          <source>J Immunol Methods</source>
          <year>2006</year>
          <volume>315</volume>
          <fpage>171</fpage>
          <lpage>184</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jim.2006.07.019</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Simmons DP, Abregu FA, Krishnan UV, Proll DF, Streltsov VA, Doughty L, Hattarki MK, Nuttall SD (2006) Dimerisation strategies for shark IgNAR single domain antibody fragments. J Immunol Methods 315:171&#x2013;184 <pub-id pub-id-type="pmid">16962608</pub-id></citation>
      </ref>
      <ref id="CR71">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Spinelli</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Frenken</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Bourgeois</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Ron</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Bos</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Verrips</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Anguille</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Cambillau</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Tegoni</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>The crystal structure of a llama heavy chain variable domain</article-title>
          <source>Nat Struct Biol</source>
          <year>1996</year>
          <volume>3</volume>
          <fpage>752</fpage>
          <lpage>757</lpage>
          <pub-id pub-id-type="doi">10.1038/nsb0996-752</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Spinelli S, Frenken L, Bourgeois D, de Ron L, Bos W, Verrips T, Anguille C, Cambillau C, Tegoni M (1996) The crystal structure of a llama heavy chain variable domain. Nat Struct Biol 3:752&#x2013;757 <pub-id pub-id-type="pmid">8784347</pub-id></citation>
      </ref>
      <ref id="CR72">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Spinelli</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Frenken</surname>
              <given-names>LG</given-names>
            </name>
            <name>
              <surname>Hermans</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Verrips</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Brown</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Tegoni</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Cambillau</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Camelid heavy-chain variable domains provide efficient combining sites to haptens</article-title>
          <source>Biochemistry</source>
          <year>2000</year>
          <volume>39</volume>
          <fpage>1217</fpage>
          <lpage>1222</lpage>
          <pub-id pub-id-type="doi">10.1021/bi991830w</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Spinelli S, Frenken LG, Hermans P, Verrips T, Brown K, Tegoni M, Cambillau C (2000) Camelid heavy-chain variable domains provide efficient combining sites to haptens. Biochemistry 39:1217&#x2013;1222 <pub-id pub-id-type="pmid">10684599</pub-id></citation>
      </ref>
      <ref id="CR73">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Stijlemans</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Conrath</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Cortez-Retamozo</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Xong</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Wyns</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Senter</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Revets</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Baetselier</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Muyldermans</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Magez</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Efficient targeting of conserved cryptic epitopes of infectious agents by single domain antibodies. African trypanosomes as paradigm</article-title>
          <source>J Biol Chem</source>
          <year>2004</year>
          <volume>279</volume>
          <fpage>1256</fpage>
          <lpage>1261</lpage>
          <pub-id pub-id-type="doi">10.1074/jbc.M307341200</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Stijlemans B, Conrath K, Cortez-Retamozo V, Van Xong H, Wyns L, Senter P, Revets H, De Baetselier P, Muyldermans S, Magez S (2004) Efficient targeting of conserved cryptic epitopes of infectious agents by single domain antibodies. African trypanosomes as paradigm. J Biol Chem 279:1256&#x2013;1261 <pub-id pub-id-type="pmid">14527957</pub-id></citation>
      </ref>
      <ref id="CR74">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Streltsov</surname>
              <given-names>VA</given-names>
            </name>
            <name>
              <surname>Varghese</surname>
              <given-names>JN</given-names>
            </name>
            <name>
              <surname>Carmichael</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Irving</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Hudson</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Nuttall</surname>
              <given-names>SD</given-names>
            </name>
          </person-group>
          <article-title>Structural evidence for evolution of shark Ig new antigen receptor variable domain antibodies from a cell-surface receptor</article-title>
          <source>Proc Natl Acad Sci USA</source>
          <year>2004</year>
          <volume>101</volume>
          <fpage>12444</fpage>
          <lpage>12449</lpage>
          <pub-id pub-id-type="doi">10.1073/pnas.0403509101</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Streltsov VA, Varghese JN, Carmichael JA, Irving RA, Hudson PJ, Nuttall SD (2004) Structural evidence for evolution of shark Ig new antigen receptor variable domain antibodies from a cell-surface receptor. Proc Natl Acad Sci USA 101:12444&#x2013;12449 <pub-id pub-id-type="pmid">15304650</pub-id></citation>
      </ref>
      <ref id="CR75">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sundberg</surname>
              <given-names>EJ</given-names>
            </name>
            <name>
              <surname>Mariuzza</surname>
              <given-names>RA</given-names>
            </name>
          </person-group>
          <article-title>Molecular recognition in antibody-antigen complexes</article-title>
          <source>Adv Protein Chem</source>
          <year>2002</year>
          <volume>61</volume>
          <fpage>119</fpage>
          <lpage>160</lpage>
        </citation>
        <citation citation-type="display-unstructured">Sundberg EJ, Mariuzza RA (2002) Molecular recognition in antibody-antigen complexes. Adv Protein Chem 61:119&#x2013;160 <pub-id pub-id-type="pmid">12461823</pub-id></citation>
      </ref>
      <ref id="CR76">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tanha</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Dubuc</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Hirama</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Narang</surname>
              <given-names>SA</given-names>
            </name>
            <name>
              <surname>MacKenzie</surname>
              <given-names>CR</given-names>
            </name>
          </person-group>
          <article-title>Selection by phage display of llama conventional V(H) fragments with heavy chain antibody V(H)H properties</article-title>
          <source>J Immunol Methods</source>
          <year>2002</year>
          <volume>263</volume>
          <fpage>97</fpage>
          <lpage>109</lpage>
          <pub-id pub-id-type="doi">10.1016/S0022-1759(02)00027-3</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Tanha J, Dubuc G, Hirama T, Narang SA, MacKenzie CR (2002) Selection by phage display of llama conventional V(H) fragments with heavy chain antibody V(H)H properties. J Immunol Methods 263:97&#x2013;109 <pub-id pub-id-type="pmid">12009207</pub-id></citation>
      </ref>
      <ref id="CR77">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Thomassen</surname>
              <given-names>YE</given-names>
            </name>
            <name>
              <surname>Meijer</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Sierkstra</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Verrips</surname>
              <given-names>CT</given-names>
            </name>
          </person-group>
          <article-title>Large-scale production of VHH antibody fragments by <italic>Saccharomyces cerevisiae</italic></article-title>
          <source>Enzyme Microb Technol</source>
          <year>2002</year>
          <volume>30</volume>
          <fpage>273</fpage>
          <lpage>278</lpage>
          <pub-id pub-id-type="doi">10.1016/S0141-0229(01)00497-5</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Thomassen YE, Meijer W, Sierkstra L, Verrips CT (2002) Large-scale production of VHH antibody fragments by Saccharomyces cerevisiae. Enzyme Microb Technol 30:273&#x2013;278 </citation>
      </ref>
      <ref id="CR78">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Thomassen</surname>
              <given-names>YE</given-names>
            </name>
            <name>
              <surname>Verkleij</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Boonstra</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Verrips</surname>
              <given-names>CT</given-names>
            </name>
          </person-group>
          <article-title>Specific production rate of VHH antibody fragments by <italic>Saccharomyces cerevisiae</italic> is correlated with growth rate, independent of nutrient limitation</article-title>
          <source>J Biotechnol</source>
          <year>2005</year>
          <volume>118</volume>
          <fpage>270</fpage>
          <lpage>277</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jbiotec.2005.05.010</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Thomassen YE, Verkleij AJ, Boonstra J, Verrips CT (2005) Specific production rate of VHH antibody fragments by Saccharomyces cerevisiae is correlated with growth rate, independent of nutrient limitation. J Biotechnol 118:270&#x2013;277 <pub-id pub-id-type="pmid">15979755</pub-id></citation>
      </ref>
      <ref id="CR79">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Utsumi</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Karush</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>The subunits of purified rabbit antibody</article-title>
          <source>Biochemistry</source>
          <year>1964</year>
          <volume>3</volume>
          <fpage>1329</fpage>
          <lpage>1338</lpage>
          <pub-id pub-id-type="doi">10.1021/bi00897a024</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Utsumi S, Karush F (1964) The subunits of purified rabbit antibody. Biochemistry 3:1329&#x2013;1338 <pub-id pub-id-type="pmid">14229677</pub-id></citation>
      </ref>
      <ref id="CR80">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Laar</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Visser</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Holster</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Lopez</surname>
              <given-names>CG</given-names>
            </name>
            <name>
              <surname>Kreuning</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Sierkstra</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Lindner</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Verrips</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Increased heterologous protein production by <italic>Saccharomyces cerevisiae</italic> growing on ethanol as sole carbon source</article-title>
          <source>Biotechnol Bioeng</source>
          <year>2007</year>
          <volume>96</volume>
          <fpage>483</fpage>
          <lpage>494</lpage>
          <pub-id pub-id-type="doi">10.1002/bit.21150</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Van de Laar T, Visser C, Holster M, Lopez CG, Kreuning D, Sierkstra L, Lindner N, Verrips T (2007) Increased heterologous protein production by Saccharomyces cerevisiae growing on ethanol as sole carbon source. Biotechnol Bioeng 96:483&#x2013;494 <pub-id pub-id-type="pmid">16948170</pub-id></citation>
      </ref>
      <ref id="CR81">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Linden</surname>
              <given-names>RH</given-names>
            </name>
            <name>
              <surname>Frenken</surname>
              <given-names>LG</given-names>
            </name>
            <name>
              <surname>Geus</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Harmsen</surname>
              <given-names>MM</given-names>
            </name>
            <name>
              <surname>Ruuls</surname>
              <given-names>RC</given-names>
            </name>
            <name>
              <surname>Stok</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Ron</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Wilson</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Davis</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Verrips</surname>
              <given-names>CT</given-names>
            </name>
          </person-group>
          <article-title>Comparison of physical chemical properties of llama VHH antibody fragments and mouse monoclonal antibodies</article-title>
          <source>Biochim Biophys Acta</source>
          <year>1999</year>
          <volume>1431</volume>
          <fpage>37</fpage>
          <lpage>46</lpage>
        </citation>
        <citation citation-type="display-unstructured">Van der Linden RH, Frenken LG, De Geus B, Harmsen MM, Ruuls RC, Stok W, de Ron L, Wilson S, Davis P, Verrips CT (1999) Comparison of physical chemical properties of llama VHH antibody fragments and mouse monoclonal antibodies. Biochim Biophys Acta 1431:37&#x2013;46 <pub-id pub-id-type="pmid">10209277</pub-id></citation>
      </ref>
      <ref id="CR82">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Linden</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Geus</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Stok</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Bos</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Wassenaar</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Verrips</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Frenken</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
          <article-title>Induction of immune responses and molecular cloning of the heavy chain antibody repertoire of <italic>Lama glama</italic></article-title>
          <source>J Immunol Methods</source>
          <year>2000</year>
          <volume>240</volume>
          <fpage>185</fpage>
          <lpage>195</lpage>
          <pub-id pub-id-type="doi">10.1016/S0022-1759(00)00188-5</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Van der Linden R, De Geus B, Stok W, Bos W, Van Wassenaar D, Verrips T, Frenken L (2000a) Induction of immune responses and molecular cloning of the heavy chain antibody repertoire of Lama glama. J Immunol Methods 240:185&#x2013;195 <pub-id pub-id-type="pmid">10854612</pub-id></citation>
      </ref>
      <ref id="CR83">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Linden</surname>
              <given-names>RH</given-names>
            </name>
            <name>
              <surname>Geus</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Frenken</surname>
              <given-names>GJ</given-names>
            </name>
            <name>
              <surname>Peters</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Verrips</surname>
              <given-names>CT</given-names>
            </name>
          </person-group>
          <article-title>Improved production and function of llama heavy chain antibody fragments by molecular evolution</article-title>
          <source>J Biotechnol</source>
          <year>2000</year>
          <volume>80</volume>
          <fpage>261</fpage>
          <lpage>270</lpage>
          <pub-id pub-id-type="doi">10.1016/S0168-1656(00)00274-1</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Van der Linden RH, De Geus B, Frenken GJ, Peters H, Verrips CT (2000b) Improved production and function of llama heavy chain antibody fragments by molecular evolution. J Biotechnol 80:261&#x2013;270 <pub-id pub-id-type="pmid">10949316</pub-id></citation>
      </ref>
      <ref id="CR84">
        <citation citation-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Vaart</surname>
              <given-names>JM</given-names>
            </name>
          </person-group>
          <person-group person-group-type="editor">
            <name>
              <surname>O'Brien</surname>
              <given-names>PM</given-names>
            </name>
            <name>
              <surname>Aitken</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Expression of VHH antibody fragments in Saccharomyces cerevisiae</article-title>
          <source>Methods in molecular biology, vol 178. Antibody phage display: methods and protocols</source>
          <year>2002</year>
          <publisher-loc>Totowa, NJ</publisher-loc>
          <publisher-name>Humana</publisher-name>
          <fpage>359</fpage>
          <lpage>366</lpage>
        </citation>
        <citation citation-type="display-unstructured">Van der Vaart JM (2002) Expression of VHH antibody fragments in Saccharomyces cerevisiae. In: O'Brien PM, Aitken R (eds) Methods in molecular biology, vol 178. Antibody phage display: methods and protocols. Humana, Totowa, NJ, pp 359&#x2013;366 </citation>
      </ref>
      <ref id="CR85">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vaart</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Pant</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Wolvers</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Bezemer</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Hermans</surname>
              <given-names>PW</given-names>
            </name>
            <name>
              <surname>Bellamy</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Sarker</surname>
              <given-names>SA</given-names>
            </name>
            <name>
              <surname>Logt</surname>
              <given-names>CP</given-names>
            </name>
            <name>
              <surname>Svensson</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Verrips</surname>
              <given-names>CT</given-names>
            </name>
            <name>
              <surname>Hammarstrom</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Klinken</surname>
              <given-names>BJ</given-names>
            </name>
          </person-group>
          <article-title>Reduction in morbidity of rotavirus induced diarrhoea in mice by yeast produced monovalent llama-derived antibody fragments</article-title>
          <source>Vaccine</source>
          <year>2006</year>
          <volume>24</volume>
          <fpage>4130</fpage>
          <lpage>4137</lpage>
          <pub-id pub-id-type="doi">10.1016/j.vaccine.2006.02.045</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Van der Vaart JM, Pant N, Wolvers D, Bezemer S, Hermans PW, Bellamy K, Sarker SA, van der Logt CP, Svensson L, Verrips CT, Hammarstrom L, van Klinken BJ (2006) Reduction in morbidity of rotavirus induced diarrhoea in mice by yeast produced monovalent llama-derived antibody fragments. Vaccine 24:4130&#x2013;4137 <pub-id pub-id-type="pmid">16616802</pub-id></citation>
      </ref>
      <ref id="CR86">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Verheesen</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>ten Haaft</surname>
              <given-names>MR</given-names>
            </name>
            <name>
              <surname>Lindner</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Verrips</surname>
              <given-names>CT</given-names>
            </name>
            <name>
              <surname>Haard</surname>
              <given-names>JJ</given-names>
            </name>
          </person-group>
          <article-title>Beneficial properties of single-domain antibody fragments for application in immunoaffinity purification and immuno-perfusion chromatography</article-title>
          <source>Biochim Biophys Acta</source>
          <year>2003</year>
          <volume>1624</volume>
          <fpage>21</fpage>
          <lpage>28</lpage>
        </citation>
        <citation citation-type="display-unstructured">Verheesen P, ten Haaft MR, Lindner N, Verrips CT, de Haard JJ (2003) Beneficial properties of single-domain antibody fragments for application in immunoaffinity purification and immuno-perfusion chromatography. Biochim Biophys Acta 1624:21&#x2013;28 <pub-id pub-id-type="pmid">14642809</pub-id></citation>
      </ref>
      <ref id="CR87">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Verheesen</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Roussis</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Haard</surname>
              <given-names>HJ</given-names>
            </name>
            <name>
              <surname>Groot</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Stam</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>den Dunnen</surname>
              <given-names>JT</given-names>
            </name>
            <name>
              <surname>Frants</surname>
              <given-names>RR</given-names>
            </name>
            <name>
              <surname>Verkleij</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Verrips</surname>
              <given-names>CT</given-names>
            </name>
            <name>
              <surname>Maarel</surname>
              <given-names>SM</given-names>
            </name>
          </person-group>
          <article-title>Reliable and controllable antibody fragment selections from camelid non-immune libraries for target validation</article-title>
          <source>Biochim Biophys Acta</source>
          <year>2006</year>
          <volume>1764</volume>
          <fpage>1307</fpage>
          <lpage>1319</lpage>
        </citation>
        <citation citation-type="display-unstructured">Verheesen P, Roussis A, de Haard HJ, Groot AJ, Stam JC, den Dunnen JT, Frants RR, Verkleij AJ, Verrips CT, van der Maarel SM (2006) Reliable and controllable antibody fragment selections from camelid non-immune libraries for target validation. Biochim Biophys Acta 1764:1307&#x2013;1319 <pub-id pub-id-type="pmid">16872921</pub-id></citation>
      </ref>
      <ref id="CR88">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Vu</surname>
              <given-names>KB</given-names>
            </name>
            <name>
              <surname>Ghahroudi</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Wyns</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Muyldermans</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Comparison of llama VH sequences from conventional and heavy chain antibodies</article-title>
          <source>Mol Immunol</source>
          <year>1997</year>
          <volume>34</volume>
          <fpage>1121</fpage>
          <lpage>1131</lpage>
          <pub-id pub-id-type="doi">10.1016/S0161-5890(97)00146-6</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Vu KB, Ghahroudi MA, Wyns L, Muyldermans S (1997) Comparison of llama VH sequences from conventional and heavy chain antibodies. Mol Immunol 34:1121&#x2013;1131 <pub-id pub-id-type="pmid">9566760</pub-id></citation>
      </ref>
      <ref id="CR89">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ward</surname>
              <given-names>ES</given-names>
            </name>
            <name>
              <surname>Gussow</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Griffiths</surname>
              <given-names>AD</given-names>
            </name>
            <name>
              <surname>Jones</surname>
              <given-names>PT</given-names>
            </name>
            <name>
              <surname>Winter</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli</article-title>
          <source>Nature</source>
          <year>1989</year>
          <volume>341</volume>
          <fpage>544</fpage>
          <lpage>546</lpage>
          <pub-id pub-id-type="doi">10.1038/341544a0</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Ward ES, Gussow D, Griffiths AD, Jones PT, Winter G (1989) Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli. Nature 341:544&#x2013;546 <pub-id pub-id-type="pmid">2677748</pub-id></citation>
      </ref>
      <ref id="CR90">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Whitlow</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Bell</surname>
              <given-names>BA</given-names>
            </name>
            <name>
              <surname>Feng</surname>
              <given-names>SL</given-names>
            </name>
            <name>
              <surname>Filpula</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Hardman</surname>
              <given-names>KD</given-names>
            </name>
            <name>
              <surname>Hubert</surname>
              <given-names>SL</given-names>
            </name>
            <name>
              <surname>Rollence</surname>
              <given-names>ML</given-names>
            </name>
            <name>
              <surname>Wood</surname>
              <given-names>JF</given-names>
            </name>
            <name>
              <surname>Schott</surname>
              <given-names>ME</given-names>
            </name>
            <name>
              <surname>Milenic</surname>
              <given-names>DE</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>An improved linker for single-chain Fv with reduced aggregation and enhanced proteolytic stability</article-title>
          <source>Protein Eng</source>
          <year>1993</year>
          <volume>6</volume>
          <fpage>989</fpage>
          <lpage>995</lpage>
          <pub-id pub-id-type="doi">10.1093/protein/6.8.989</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Whitlow M, Bell BA, Feng SL, Filpula D, Hardman KD, Hubert SL, Rollence ML, Wood JF, Schott ME, Milenic DE et al (1993) An improved linker for single-chain Fv with reduced aggregation and enhanced proteolytic stability. Protein Eng 6:989&#x2013;995 <pub-id pub-id-type="pmid">8309948</pub-id></citation>
      </ref>
      <ref id="CR91">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yau</surname>
              <given-names>KY</given-names>
            </name>
            <name>
              <surname>Groves</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Sheedy</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Tanha</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>MacKenzie</surname>
              <given-names>CR</given-names>
            </name>
            <name>
              <surname>Jermutus</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Hall</surname>
              <given-names>JC</given-names>
            </name>
          </person-group>
          <article-title>Selection of hapten-specific single-domain antibodies from a non-immunized llama ribosome display library</article-title>
          <source>J Immunol Methods</source>
          <year>2003</year>
          <volume>281</volume>
          <fpage>161</fpage>
          <lpage>175</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jim.2003.07.011</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Yau KY, Groves MA, Li S, Sheedy C, Lee H, Tanha J, MacKenzie CR, Jermutus L, Hall JC (2003) Selection of hapten-specific single-domain antibodies from a non-immunized llama ribosome display library. J Immunol Methods 281:161&#x2013;175 <pub-id pub-id-type="pmid">14580890</pub-id></citation>
      </ref>
      <ref id="CR92">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yoo</surname>
              <given-names>TJ</given-names>
            </name>
            <name>
              <surname>Roholt</surname>
              <given-names>OA</given-names>
            </name>
            <name>
              <surname>Pressman</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>Specific binding activity of isolated light chains of antibodies</article-title>
          <source>Science</source>
          <year>1967</year>
          <volume>157</volume>
          <fpage>707</fpage>
          <lpage>709</lpage>
          <pub-id pub-id-type="doi">10.1126/science.157.3789.707</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Yoo TJ, Roholt OA, Pressman D (1967) Specific binding activity of isolated light chains of antibodies. Science 157:707&#x2013;709 <pub-id pub-id-type="pmid">6028046</pub-id></citation>
      </ref>
      <ref id="CR93">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zhang</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Tanha</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Hirama</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Khieu</surname>
              <given-names>NH</given-names>
            </name>
            <name>
              <surname>To</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Tong-Sevinc</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Stone</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Brisson</surname>
              <given-names>JR</given-names>
            </name>
            <name>
              <surname>MacKenzie</surname>
              <given-names>CR</given-names>
            </name>
          </person-group>
          <article-title>Pentamerization of single-domain antibodies from phage libraries: a novel strategy for the rapid generation of high-avidity antibody reagents</article-title>
          <source>J Mol Biol</source>
          <year>2004</year>
          <volume>335</volume>
          <fpage>49</fpage>
          <lpage>56</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jmb.2003.09.034</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Zhang J, Tanha J, Hirama T, Khieu NH, To R, Tong-Sevinc H, Stone E, Brisson JR, MacKenzie CR (2004) Pentamerization of single-domain antibodies from phage libraries: a novel strategy for the rapid generation of high-avidity antibody reagents. J Mol Biol 335:49&#x2013;56 <pub-id pub-id-type="pmid">14659739</pub-id></citation>
      </ref>
      <ref id="CR94">
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zwick</surname>
              <given-names>MB</given-names>
            </name>
            <name>
              <surname>Parren</surname>
              <given-names>PW</given-names>
            </name>
            <name>
              <surname>Saphire</surname>
              <given-names>EO</given-names>
            </name>
            <name>
              <surname>Church</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Scott</surname>
              <given-names>JK</given-names>
            </name>
            <name>
              <surname>Dawson</surname>
              <given-names>PE</given-names>
            </name>
            <name>
              <surname>Wilson</surname>
              <given-names>IA</given-names>
            </name>
            <name>
              <surname>Burton</surname>
              <given-names>DR</given-names>
            </name>
          </person-group>
          <article-title>Molecular features of the broadly neutralizing immunoglobulin G1 b12 required for recognition of human immunodeficiency virus type 1 gp120</article-title>
          <source>J Virol</source>
          <year>2003</year>
          <volume>77</volume>
          <fpage>5863</fpage>
          <lpage>5876</lpage>
          <pub-id pub-id-type="doi">10.1128/JVI.77.10.5863-5876.2003</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Zwick MB, Parren PW, Saphire EO, Church S, Wang M, Scott JK, Dawson PE, Wilson IA, Burton DR (2003) Molecular features of the broadly neutralizing immunoglobulin G1 b12 required for recognition of human immunodeficiency virus type 1 gp120. J Virol 77:5863&#x2013;5876 <pub-id pub-id-type="pmid">12719580</pub-id></citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>